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Abstract
ORCTL3 was recently isolated as a gene with a tumour-specific apopto-
sis activity. Its transfection into transformed cells elicits an apoptosis re-
sponse, while normal cells remain unaffected. In this study I show that
ORCTL3 is activated for apoptosis induction by individual tumourigenic
mutations in renal cells. Its activity is also shared by other so-called an-
ticancer genes such as Mda-7/IL-24, TRAIL, Apoptin, and Par-4. This
effect is independent of the tumour cells’ proliferation status and is me-
diated by an incomplete ER stress response, characterised by ATF4, but
not BiP accumulation. ATF4 upregulation and also the ARCosome, a
recently discovered caspase-8-activation complex, are required for apop-
tosis by ORCTL3. For its effect, ORCTL3 targets the enzyme stearoyl-
CoA desaturase-1 (SCD-1) that is involved in the fatty acid metabolism.
This is evidenced by the inhibition of apoptosis induced through ORCTL3
when the SCD-1 product oleic acid is exogenously supplemented and by the
replication of its tumour-specific effect upon chemical inhibition of SCD-
1. ORCTL3’s activity to specifically target tumour cells is caused by the
transmembrane domains 3 and 4 of the mouse, but not the human, gene
and critically depends on the expression level of the ORCTL3 protein. Fi-
nally, an adenovirus carrying the expression cassette of ORCTL3 leads to
an efficient expression and therefore, substantial and specific destruction
of primary renal tumour cells compared to their normal counterparts. My
results indicate that ORCTL3 induces tumour-specific apoptosis by specif-
ically targeting cancer metabolism and suggest novel therapeutic interfer-
ences for renal tumours.
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1 Introduction
1.1 Apoptosis and Cancer
1.1.1 Apoptosis, a Necessary Part of the Life Cycle
“Destroying is a necessary function in life. Everything has its season, and
all things eventually lose their effectiveness and die”
- Margaret J. Wheatley
For every major construction, substantial demolition of the old buildings
has to take place in order to make way for new developments. This de-
struction process has to be safe, precise, organized, and quick to make
sure it does not affect the surrounding structures and does not leave any
debris that might affect the new constructions. When a similar process
takes place at the cellular level in living organisms it is called apoptosis[1].
Apoptosis, a Greek word that means “falling off” of petals or leaves from
plants and trees, is the common term used to describe a process of pro-
grammed cell death. The phenomenon was first described in 1842 by the
German naturalist Karl Vogt while studying the development of the tadpole
of the midwife toad[2]. However, it was not until 1972, when Kerr, Wyl-
lie and Currie introduced the name “apoptosis”. In their landmark study,
Kerr et al. explained the structural and morphological changes that take
place during the process, and the physiological and pathological relevance
of the newly-found mechanism[3]. It has become, since then, known to
be a tightly controlled physiological process that is regulated by complex
molecular signalling[4]. More knowledge about the developmental path-
way of apoptosis was gained when Ellis and Horvitz cloned the responsible
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death genes (ced-3 and ced-4 genes) from Caenorhabditis elegans in 1999,
and found that the functions of these genes are required for the initia-
tion of programmed cell death and the loss of their functions results in cell
survival[5]. Ced-3 gene encodes a cysteine protease, is homologous to mem-
bers of the caspase protease family in mammalian cells, and is activated
by Ced-4[6]. This activation can be blocked by the Ced-9 protein which
is homologous to mammalian Bcl-2. This homology and conservation be-
tween nematode and mammalian cell death genes in sequence and function
suggest that apoptosis originated during ancient evolution and that it is
a necessary and conserved mechanism for the development of both worms
and humans[7].
Apoptosis is a cellular homeostasis mechanism used by multi-cellular or-
ganisms to dispose of unwanted cells in order to ensure correct development
in the early stages of life and organ function in the adult[1]. During em-
bryonic development apoptosis is important to sculpture organ shape, e.g.
carve out the interdigital tissues of the fingers and the toes. Moreover, cells
that fail to establish functional synaptic connections in the nervous system
or productive antigen specificities in the immune system undergo apoptotic
death to ensure complete development of both systems during intra-uterine
growth of the embryo[8]. During adulthood, apoptosis is responsible for the
death of 10 billion cells every day to keep balance with the number of the
newly produced cells from stem cells[8]. The new cell in this case replaces
the old one in a matter of hours after the disposal of the cellular debris by
professional phagocytes[1, 3]. Apoptosis is also a physiological response to
many stimuli, including irreparable DNA damage where it serves to clean
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up damaged cells in a tightly controlled manner that minimizes damage
and disruption to neighbouring cells[1, 3, 8].
A precisely regulated balance between cell division, cell cycle arrest, dif-
ferentiation and apoptosis is absolutely required for the steadiness of the
proliferation rate of any given cell population[9]. Any disruption of this
process such as too little or too much cell death may lead to pathology.
Moreover, because apoptosis, like any other metabolic or developmental
program, is genetically encoded, any gain- or loss-of-function mutation in
the genes involved in the apoptotic pathways can be a key pathological
event that results in disease[10, 11]. In fact, defective apoptosis pathways
are now thought to be involved in a long list of human diseases. Increased
apoptosis can be found in a number of neurodegenerative diseases such as
Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis,
autoimmune diseases such as hepatitis and graft versus host disease, AIDS,
and ischaemic injury after myocardial infarction and stroke. On the other
hand, decreased apoptosis can be found in some other autoimmune disor-
ders such as systemic lupus erythematosus, some viral infections, and most
importantly in many malignancies[8, 12] (see below).
The most distinctive feature of apoptosis, compared to other forms of
cell death, is the fact that apoptosis is a process that elicits no anti-
inflammatory responses[13]. This is a result of the characteristic morpho-
logical and biochemical aspects of apoptosis. Observed by light and electron
microscopy, the dying cell starts to detach from other surrounding cells and
the extracellular matrix, rounds up, and shrinks (pyknosis). The plasma
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membrane then starts to show projections and blebs (pseudopods) and the
nucleus and chromatin start to condense. Finally, the nucleus disassembles
into small fragments (karyorrhexis) and the entire cell breaks down into
membrane-bound vesicles known as apoptotic bodies[14, 15]. These are
rapidly engulfed by phagocytes for immediate clearance[16]. Figure 1.1.
Phagocytes are usually able to discriminate between living and dying cells
through the recognition of specific ligands on the dying cells and the loss
of inhibitory signals in the dying cells that might normally protect living
cells from clearance[16]. Whilst the term “apoptosis” should exclusively
be applied to cell death events that demonstrate several of the above mor-
phological changes[17], if apoptotic bodies are not immediately engulfed
by phagocytes, they undergo a process that is called “secondary necro-
sis”, which is a post-apoptotic cytolysis that might induce inflammatory
response[16].
According to the Nomenclature Committee on Cell Death (NCDD), the
cell is considered dead in the presence of any of the following molecular
or morphological criteria: the loss of the plasma membrane integrity, the
complete fragmentation of the cell and its nucleus, or the engulfment of the
“dead” cell or its fragments by an adjacent cell.
These guidelines to define a dead cell were proposed because of the ab-
sence of a clearly characterized biochemical event that can be considered
as the point-of-no-return. However, since apoptosis is the most widely
studied type of cell death, the morphological changes that define apoptosis
helped in investigating the biochemistry and signal transduction of apop-
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tosis since these changes are the result of the activation of the intracellular
signal transduction pathways that kill the cell and clear the corpse[17].
Cell death can be classified according to its enzymological criteria, func-
tional aspects and immunological characteristics. However, the most com-
monly used classification of cell death is the morphological appearance
classification where it may be described as apoptotic, necrotic, autophagic,
or associated with mitosis[17].
Necrosis:
Necrosis is a form of cell death that, for a long time, has been thought to
be an accidental, unrestrained process[17]. However, recent evidence shows
that the process of necrosis might be finely controlled by a number of signal
transduction pathways and catabolic mechanisms, such as the involvement
of the death domain receptors, Fas/CD95, TNFR1, and TRAIL-R and
the Toll-Like receptors, TLR3 and TLR4[17]. The discovery of these reg-
ulatory signals lead to the introduction of the term “necroptosis”, which
can be distinguished from the accidental form of necrosis by its response
to RIP1 inhibition that can only prevent programmed necrosis. Necrosis
can be morphologically characterised by the gain in cell volume (oncosis),
swelling of organelles, rupture of plasma membrane, and subsequent loss of
intracellular contents. Figure 1.2.
Autophagy:
Autophagy, from the Greek “auto” or oneself and “phagy”, is a process of
self-cannibalization where cells detain their own cytoplasm and organelles
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and consume them in lysosomes to produce new molecules to generate en-
ergy and build new proteins and membranes[18]. This process replaces im-
paired cellular components with fresh ones to sustain the health of cells and
it provides an internal source of nutrients to generate energy for survival in
case of starvation. It is characterized by the confiscation of damaged cellu-
lar material within autophagosomes, two-membraned vesicles that contain
degenerating cytoplasmic organelles or cytosol, for degradation by lyso-
somes; a fusion that generates autolysosomes. In the autolysosomes, the
membrane and the content of autophagosomes are degraded by acidic lyso-
somal hydrolases[17]. The accumulation of autophagosomes does not neces-
sarily indicate an induction of the autophagic pathway as autophagosomes
might accumulate when their fusion to the lysosomes is blocked despite an
autophagy inhibition[17]. Autophagy can be morphologically defined by
the absence of chromatin condensation, massive autophagic vacuolization
of the cytoplasm, and no association with phagocytes despite the linguistic
invitation[17]. Autophagy can promote cell survival, but only in specific
cases, when it occurs in excess, after a prolonged degeneration of the cyto-
plasm beyond a point of no return, autophagy destructs the cells.
Cornification:
Also known as “kernatinisation” and “cornified envelope formation”, corni-
fication is a very specific form of programmed cell death that takes place
in the epidermis and results in the formation of corneocytes (dead ker-
atinocytes) containing a mixture of specific proteins and lipids, which are
required for the function of the cornified skin layer[17].
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Other atypical cell death modes include mitotic catastrophe, anoikis, exci-
totoxicity, Wallerian degeneration, praptosis, pyroptosis, pyronecrosis, and
entosis[17].
Figure 1.1: Diagram from Kerr et al. (1972) to illustrate the morphological
features of apoptosis.
25
Figure 1.2: Illustration of apoptosis and necrosis according to Kerr et al.
(1995). From S. Van Cruchten and W. Van Broeck (2002)
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1.1.2 Apoptosis Pathways
Apoptosis is a highly complex and sophisticated mechanism that is genet-
ically pre-programmed and can occur as a response to external or cellular
stimuli. It involves an energy-dependent cascade of molecular events that
are mainly choreographed by members of a family of cysteine proteases
called caspases (Cysteine ASPartate-Specific ProteASEs)[19]. These cas-
cades of events normally lead to the three main characteristic features of
apoptosis: cleavage or hydrolysis of cellular proteins, nuclear DNA break-
down, and apoptotic cell recognition by phagocytic cells[20].
Caspases, the executioners of apoptosis, can be activated through at least
three known pathways depending on the death trigger signal, the cell type,
and the equilibrium between anti-apoptotic and pro-apoptotic signals[20].
Only two of these pathways, the death receptor pathway (extrinsic) and
mitochondrial (intrinsic), are widely understood and have been described
in details[21, 22]. The third is less understood and is known as the en-
doplasmic reticulum (ER) intrinsic pathway[23, 24]. Although, all three
pathways involve totally different proteins and series of events, a cross-talk
between them is rather possible, especially with the ER intrinsic pathway
which eventually activates the intrinsic mitochondrial pathway[20].
The Extrinsic Pathway
Also known as the death receptor pathway, the extrinsic pathway is usually
activated by the binding of the pro-apoptotic death receptors (DRs) that
belong to the tumour necrosis factor (TNF) receptor superfamily, e.g. Fas
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and TNFR1, on the cell membrane to their specific ligands such as Fas
ligand (FasL) and TNF-α[25, 26, 27, 28, 29, 30]. This binding leads to the
activation of the intracellular part of the DRs, known as the death domain
(DD), which, in turn, form a binding site for the binding of a DR-specific
adapter protein, such as FADD or TRADD. The binding of the ligand,
receptor, and adaptor protein forms a complex called death-inducing sig-
nalling complex (DISC). Formation of DISC also involves the recruitment
and assembly of initiator caspases-8 and -10, and this is the necessary step
to activate the caspase cascade and execute apoptosis[31, 32, 33, 34]. Fig-
ure 1.3.
Figure 1.3: Schematic representation of caspase-3 activation and apopto-
sis induction by the extrinsic pathway involving the binding of the death
receptors with their specific ligands.
The Intrinsic Pathway
The other caspase activation pathway is the mitochondrial apoptosome-
driven caspase activation pathway. This pathway is usually initiated by
stress stimuli such as cytotoxic drugs, ionizing radiation, heat shock, DNA
damage, radical oxygen species, nutrient deprivation, and cytokines[35].
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These stimuli eventually lead to apoptosis when the balance between the ac-
tivities of pro-apoptotic and anti-apoptotic members of the B-cell lymphoma-
2 (Bcl-2) proteins superfamily is disturbed. Bcl-2 family members are lo-
calised on the outer mitochondrial membranes to control membrane perme-
ability, through the formation of pores or ion channels[36], and therefore,
the release of the pro-apoptotic substances from the mitochondria such as
cytochrome-c. The anti-apoptotic members of the Bcl-2 protein family,
Bcl-2 and Bcl-xL, protect the mitochondrial outer membrane permeability
by stimulating ADP/ATP exchange to prevent the opening of a perme-
ability transition pore[37]. On the other hand, pro-apoptotic proteins of
the Bcl-2 family initiate apoptosis by blocking the binding of Bcl-2 and
Bcl-xL to their mitochondrial binding sites or by activating pro-apoptotic
Bax/Bak[38]. Once the balance between these two groups of proteins is
disturbed, the mitochondrial outer membrane permeability is compromised
and this leads to the release of cytochrome-c, which assembles with a cy-
tosolic protein called apoptosis protease-activating factor-1 (Apaf-1). This
complex combines with and activates procaspase-9 to form an apoptosome,
which then activates procaspase-3[39].
The cross-talk between the extrinsic and the intrinsic pathways is usually
mediated by Bid. Inactive Bid is found in the cytoplasm and is activated
when cleaved by caspase-8 (from the extrinsic pathway). Active Bid (t-
Bid) then interacts with Bax to make it structurally comparable to the
anti-apoptotic protein Bcl-2, allowing it to translocate to the mitochon-
dria, compromise the mitochondrial outer membrane integrity and trigger
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the intrinsic apoptosis pathway[40, 41, 42, 43]. Figure 1.4.
Figure 1.4: Schematic representation of caspase-3 activation and apoptosis
induction by the intrinsic pathway involving cytochrome-c release from the
mitochondria and Apoptosome formation. The cross talk between the ex-
trinsic and the intrinsic pathway through Bid activation is also highlighted.
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Other Alternative Pathways
Other described pathways of apoptosis involve an indirect and unconven-
tional disruption of the mitochondria that is either specific to one cell type
or does not result in the traditional caspase cascade activation[20]. For
instance, apoptosis mediated by serine protease Granzyme B is an im-
mune surveillance mechanism used by T-cells and natural killer cells to
clear virally infected to malignantly transformed cells[44]. In this case,
activated Granzyme B can cleave a number of caspase targets and other
proteins to induce apoptosis in a mitochondrial-dependent fashion. Simi-
larly, Granzyme A pathway provides a back-up system when Granzyme B is
inhibited in these cells[45]. The mitochondrial outer membrane can also be
disrupted by the cleavage of sphingomyelin, a member of the phospholipid
bilayer, into ceramide by the activation of sphingomyelinases as a result
of various cellular stresses[46, 47, 44]. Elevation of ceramide results in in-
creased mitochondrial membrane permeability, and hence, cytochrome-c re-
lease and caspase-9 activation[44]. The release of other mitochondrial pro-
death substances such as, apoptosis inducing factor[48], Smac/DIABLO[49,
50, 51], endonuclease G, HtrA2/Omi and other procaspases[52] can also re-
sult from the increase of mitochondrial outer membrane permeability. Some
of these molecules can cause caspase-independent chromatin condensation
and DNA fragmentation[20, 53].
Caspase Cascade
Caspases, the interleukin-1β-converting enzyme family proteases, are all
aspartate-specific cysteine proteases that share a conservative pentapep-
tide active site ”QACXG” (X=R,Q orD) and are usually present as zymo-
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gen precursors, procaspases. So far, fourteen caspases have been identified
which are known for their high homology to the C.elegans cell death gene
Ced-3[54]. Seven of these caspases are involved in apoptosis pathways (ini-
tiators and executioners) whereas the remaining six caspases are mainly
associated with inflammatory responses and caspase-14 is especially linked
to epithelial cell differentiation. However, based on their homology in amino
acid sequences, they can be divided into three subfamilies: apoptosis acti-
vators, apoptosis executioners, and inflammatory mediators[54].
As shown above, the activation of the extrinsic and the intrinsic pathways
of apoptosis lead to the activation of procaspase-8, -9, and/or-10. Includ-
ing also caspase-2, these are known as the initiator caspases and are closely
coupled to the pro-apoptotic signals. Once activated, their death domains,
long pro-domains contain the death effector domain (DED) in caspase-
8 and -10 and the caspase recruitment domain (CARD) in procaspase-2
and -9, are involved in downstream caspase cascade regulation and pro-
caspases activation through protein-protein interaction[54]. Downstream
procaspases include effector (executioner) caspases, caspase-3, -6, and -7.
When active, these caspases can subsequently cleave specific cellular pro-
teins such as PARP [poly(ADP-ribose) polymerase], lamin, fordrin, and
Bcl-2 resulting in the typical morphological hallmarks of apoptosis[54].
These executioner caspases can also amplify the function of the upstream
initiator caspases. Moreover, additional amplifying loops can result from
the cross-talks between the two signalling pathways explained above[55].
The other members of the caspases family (caspase-1, 4, 5, 11, 12, 13,
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and 14) are known as the inflammatory mediators. Apart from caspase-14,
which has been mostly associated with epithelial cell differentiation rather
than inflammation, inflammatory caspases are associated with immune re-
sponses to microbial pathogens and the activation of proinflammatory cy-
tokines IL-1β, IL-18, IL-1F7b, and NOD-LRR members[54, 56].
1.1.3 Apoptosis and the Endoplasmic Reticulum Stress
“Arguably” the third and the least understood apoptosis pathway is the
intrinsic ER pathway. Endoplasmic Reticulum (ER) is large membrane-
enclosed cellular organelle where the folding of proteins, synthesis of lipids
and sterols, and storage of free calcium take place[57]. ER stress results
from the increase of the demand for protein folding beyond the capacity of
the ER due to physiological or pathological stresses such as increased pro-
tein secretory load or the presence of mutated proteins that cannot properly
fold in the ER[57]. This stress usually leads to an evolutionary conserved
response called the unfolded protein response (UPR), a collection of signal
transduction pathways that take place to help adapt to the changing en-
vironment and restore normal ER homeostasis[57]. When adaptation fails,
due to excessive or prolonged ER stress, a signal for apoptosis is usually
triggered to clear the dysfunctional cells[58].
The accumulation of the unfolded proteins in the ER leads to their binding
to the ER chaperone Grp78 (BiP) that normally holds ER transmembrane
proteins to prevent their aggregation. The release of BiP from these critical
transmembrane proteins (PERK, Ire1, and ATF6) results in their aggre-
gation and the initiation of the UPR[58]. This step initiates a cascade of
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protein activation in an effort to restore ER’s normal function.
When PERK (PKR-like ER kinase) is released from BiP, it oligomerizes
in the ER membrane to induce its autophosphorylation and its kinase do-
main activation. Active PERK phosphorylates and inactivates eIFα to
shut off overall mRNA translation to reduce ER protein overload. Nev-
ertheless, certain mRNAs are selectively actively translated such as the
mRNA encoding transcription factor ATF4, which, in turn, activates the
transcription of other UPR gene[58].
Similarly, when Ire1 is released from BiP, it oligomerizes in the ER mem-
brane to process an intron from the mRNA of the X box protein-1 (XBP-1)
enabling it to be translated to the 41-kDa XBP-1 protein. Spliced XBP-1,
in turn, activates the promoters of a number of genes that are involved
in clearing misfolded proteins[59, 60, 61]. In addition, free Ire1 can bind
to c-Jun N-terminal inhibitory kinase (JIK) and the adaptor protein TNF
receptor-associated factor 2 (TRAF2) which activates protein kinases in-
volved in inflammatory responses such as Ask1 that activates JNK and
kinases linked to the activation of NF-κB[58, 62, 63, 64].
Finally, the release of ATF6 from BiP results in its translocation from the
ER to Golgi apparatus where it is cleaved by proteases and released to the
cytosol and subsequently to the nucleus to regulate gene expression includ-
ing an increase in XBP-1 mRNA transcription[58, 65].
All above activities are natural attempts of the ER to adapt to the stress
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and provide protection from cell death. However, ER stress triggers apopto-
sis when protein misfolding stress is persistent or excessive through several
proposed mechanisms.
The best described mechanism is caspase-12 activation by ER stress[66].
In normal cells, TRAF2 is bound to procaspase-12 keeping it inactive. Ac-
tivation of TRAF2, by free Ire1 as mentioned above, results in its dissocia-
tion from procaspase-12 and the activation of caspase-12[64, 67, 68]. Active
caspase-12 activates procaspase-9, which subsequently activates procaspase-
3, -6, and -7[20], independently from the mitochondria.
Ire1 -TRAF2 complex can also activate Ask1, a kinase that activates JNK
and p38 MAPK. JNK-mediated phosphorylation activates the proapoptotic
protein Bim[69, 70, 71] and inhibits the antiapoptotic protein Bcl-2[72].
A cross-talk between these mechanisms and the mitochondrial intrinsic
pathway was also reported. For instance, caspase-12 was found to cause
a release of cytochrome-c from the mitochondria[67]. Moreover, ER stress
was shown to activate c-Abl tyrosine kinase that also releases cytochrome-
c[68]. Finally, Bak, a pro-apoptotic Bcl-2 family protein, has been re-
ported to cause calcium depletion in the ER, which can cause caspase-12
activation[73].
The above caspase-12 activation mechanism might be well established in
rodents. However, in humans, because of the absence of caspase-12, the
relevance of caspase-12 to apoptosis induced by ER stress is question-
35
able. Caspase-12 gene is inactive in humans due to a disruption by a
stop codon[74]. Nevertheless, some reports suggest that human caspase-4
can substitute the function of rodent caspase-12 in ER stress due to its
high homology to rodent caspase-12[58, 75].
ER stress can also induce apoptosis through the activation of the tran-
scription factor CHOP (GADD153)[76]. Expression of CHOP is usually
induced by most of UPR transcription factors including ATF4, ATF6, and
XBP-1[58]. Overexpressed CHOP induces apoptosis through a poorly de-
scribed Bcl-2-inhibitable mechanism[77, 78] that might be explained by the
disruption of expressions of several genes or an unknown nontranscriptional
function of CHOP[76, 79].
ER might also play another role in initiating and executing apoptosis
through its resident protein Bap31. Bap31 can show a proapoptotic func-
tion when its cytosolic C-terminal is cleaved by caspase-8 to produce the
short p20Bap31 protein, which transmits an apoptosis signal[80] whilst full-
length Bap31 can block apoptosis in many occasions[58, 81, 82, 83]. Figure
1.5.
1.1.4 Apoptosis and the ARCosome
The mitochondria and the ER are two main organelles associated with
apoptosis regulation in the cells. The signals discussed above show ex-
amples of how the ER communicates its apoptosis signals to the mito-
chondria. Other molecules such as Mitofusin2 and Mmm1/Mdm10, 12,
34 were also shown to facilitate a physical interaction between the two
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Figure 1.5: Simplified depiction of selected apoptotic pathways induced by
ER stress.
organelles[84, 85, 86]. On the other hand, the apoptosis signal that is
transmitted from the mitochondria to the ER is only a recent finding by
Iwasawa et al.[84].
Iwasawa et al. proposed the formation of a complex that is initiated by
a signal from the mitochondria to the ER to form a platform bridge be-
tween the two organelles. The function of this platform is to establish
a feedback loop of calcium release from the ER to activate mitochondria
for apoptosis[84, 87]. Called the ARCosome, this preformed complex is
found in normal, non-apoptotic, cells and made of an interaction between
the fission factor Fis1 from the mitochondria and Bap31 from the ER.
This interaction is responsible for the activation of procaspase-8 after it
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has been recruited to the complex, by the variant of death effector domain
(vDED) in Bap31, when applying various chemical cell death inducers[84].
The recruitment of procaspase-8 to the ARCosome results in the cleavage
of Bap31 to the pro-apoptotic p20Bap31, Ca2+ release from the ER, and
the uptake of the released Ca2+ by the mitochondria, which leads to the
disruption of the mitochondrial membrane potential and the cleavage of
PARP[84]. Figure 1.6.
Figure 1.6: Schematic illustration of the activation of the ARCosome.
A signal is transformed from mitochondrial Fis1 to the pro-apoptotic
Bap31p20 at the ER through the recruitment of capsase 8 and the cleavage
of Bap31.
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1.1.5 Disruption of Apoptosis
That’s life, I can’t deny it,
I thought of quitting,
But my heart just won’t buy it.
If I didn’t think it was worth a try,
I’d roll myself up in a big ball and die.
- Frank Sinatra (by Dean Kay and Kelly Gordon)
For cells, the decision to die is not a question whether life is worth it; in-
stead, in normal tissues of adult multicellular organisms, it is a continuous
attempt by the cells to maintain tissue homeostasis through dynamically
balancing cell proliferation and mitosis[88, 89, 3, 90, 91]. For example,
red blood cells undergo continuous renewal from haematological precursor
cells. On the other hand, neural cells have no or only limited capacity to
regenerate. Other cells such as white blood cells and reproductive cells
show an increase in expansion in response to an immediate demand such
as host defence and reproduction, respectively[92, 88]. Throughout these
cycles of cell divisions other cells undergo apoptosis to keep the total num-
ber of cells within the tissue under control. Cell proliferation and cell death
can be controlled by similar factors, such as growth factors that can either
stimulate cell division or inhibit cell death[93, 94, 95]. c-Myc, a proto-
oncogene associated with cell proliferation, can also induce apoptosis when
over expressed[96]. Moreover, the tumour suppressor gene p53 is involved
in making the decision whether the cell progresses in the cell cycle or un-
dergoes apoptosis in case of DNA damage[97].
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All of the above indicates that the balance between cell proliferation and
apoptosis is a crucial aspect to keep normal physiological homeostasis in
organisms. Any failure of cells to maintain this balance can result in a
pathological condition. Figure 1.7.
Diseases that involve disruptions in apoptosis can be classified into two
main groups: conditions in which apoptosis is increased and conditions in
which apoptosis is inhibited[88].
Diseases associated with excessive apoptosis
Neurodegenerative diseases
Many neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s
disease, amyotrophic lateral sclerosis, and retinitis pigmentosa are associ-
ated with increased apoptosis of neurons[88].
Haematological diseases
Myelodysplastic syndromes, aplastic anaemia, chronic neutropenia and se-
vere thalassaemia are all haematological disorders associated with increased
apoptotic cell death in the bone marrow[98, 99, 100]. However, the exact
mechanisms by which increased apoptosis results in these diseases are still
unknown but reports suggest the involvement of stroma cell deficiencies,
gene deregulation and direct effects of toxins or mediators of the immune
response[92].
AIDS
Caused by the Human Immunodeficiency Virus (HIV), AIDS is charac-
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terised by the imbalance between the number of CD4+ T-lymphocytes,
which undergo excessive apoptosis for so far unknown reason, and the abil-
ity of the bone marrow to generate new cells[88].
Other diseases
Excessive apoptosis is also to blame for many other diseases including poly-
cystic kidney disease[101], toxic-induced liver disease[102], ischaemic in-
juries, arthritis, osteoporosis and many other aging-related conditions[92].
Diseases associated with inhibited apoptosis
Autoimmune Diseases
Human T-cells refrain from attacking self-cells because of a negative selec-
tion process that takes place during the development of the immune system
mainly through apoptosis to delete clones of auto-reactive T-cells. Reports
show that lymphocytes of several autoimmune diseases, such as rheuma-
toid arthritis, systemic lupus erythematosus, autoimmune diabetes mellitus
and inflammatory bowel disease, are less susceptible to apoptosis in vitro
compared to cells from healthy individuals[103]. This is due to reported
mutations in genes rendering the lymphocytes resistant to apoptosis[88].
Viral infections
When cells are infected with a virus, they undergo apoptosis as a defence
mechanism to prevent the spread of the infection. This can also be trig-
gered by stimulated cytotoxic T-cells that induce apoptosis in the cells
by introducing proteases into the target cells or activating the Fas recep-
tor on its surface[104, 92]. However, some viruses express proteins that
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inhibit apoptosis by interfering with the host cell’s checkpoint that lead
to apoptosis. These viruses include cowpox virus[105, 106], Epstein-Barr
virus, adenovirus, and African swine fever virus[107, 108, 109]. The latter
three encode a protein that is structurally and functionally similar to Bcl-2.
Neoplastic diseases
Cancer is commonly referred to as a disease caused by excessive cellular
proliferation. However, dysregulation of apoptosis caused by certain ge-
netic aberrations was recently found to be involved in the clonal growth of
malignant cells[92]. (For more details see below: Apoptosis and Cancer)
1.1.6 Apoptosis and Cancer
It was the cloning and the characterisation of the Bcl-2 in the 80s that
established the connection between alterations in apoptosis and tumour
development[110, 111]. The Bcl gene was isolated from cells of a B cell
lymphoma[110] and Bcl-2 was described as an oncogene when it was first
identified at the chromosomal translocation breakpoint of t(14;18) in a hu-
man leukaemia line and later on found to be a common event in follicular
lymphoma[10]. Unlike other established oncogenes at that time, Bcl-2 was
found to be blocking programmed cell death instead of disturbing normal
proliferation[112, 113].
The second gene that was found to link apoptosis to tumourigensis is the
tumour suppressor gene p53. p53 is mutated in over 50% of all human
tumours and its mutation is often associated with advanced tumour stage
and poor prognosis[114]. It is known for its involvement as a checkpoint
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Figure 1.7: The levels of cell death and cell growth are always in balance
to maintain homeostasis in tissues. b. Low or c. Excessive apoptosis are
usually involved in the pathogenesis of various diseases.
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protein in cell cycle arrest and DNA damage response. However, a role
of p53 in cell survival and cell death was established when overexpression
of the protein resulted in apoptosis in a myeloid leukaemia cell line[115].
Moreover, endogenous p53 was subsequently found to be required for apop-
tosis induction by certain stimuli such as, radiation, hypoxia, and mitogenic
oncogenes[116, 117].
c-Myc is another oncogene that was found to be involved in oncogene-
induced apoptosis in human cancer[118]. It was first known for its role in
driving cell proliferation and preventing cell-cycle arrest in the absence of
survival factors such as serum when ectopically expressed in normal cells.
However, cells did not accumulate under these conditions; instead, c-Myc
induced a default apoptosis pathway[96, 119]. In other words, upregu-
lated Myc induces an increased proliferation that is kept under control by
a simultaneous increase in apoptosis in normal cells when levels of growth
or survival factors are limiting[119]. This induced apoptosis is referred
to as a molecular safety valve to prevent tumour development and stud-
ies on c-Myc have been unable to separate its proliferative functions from
those which promote apoptosis[120]. The exact mechanism by which Myc
induces apoptosis is not fully understood but some reports suggest that
Myc sensitises cells to apoptosis through the suppression of anti-apoptotic
proteins such as Bcl-2 and Bcl-xL[108, 118]. Nevertheless, Myc can drive
tumourigenesis when there is a double hit in the form of an increase in
the expression of Bcl-2, which is known to cooperate with Myc and block
Myc-stimulated apoptosis, or another death suppressing mechanism. This
synergy usually results in the clonal expansion of tumours that express Myc
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and Bcl-2[121, 122]. Studies on Myc suggest that the cellular context in
which Myc is expressed is of importance and should be taken into account
when developing Myc-based cancer therapies[119].
The connection between apoptosis and cancer can be summarised by the
fact that several oncogenes and anti-oncogenes have been found to regulate
apoptotic cell death[92]. A neoplastic lesion is usually induced when onco-
genes that promote cell proliferation cooperate with those that inhibit cell
death[92].
The importance of targeting apoptosis in cancer therapy started to get
some attention in the 1970s when pathologists noticed cell death with
morphological features of apoptosis in cells treated with radiation and
chemotherapy[123]. Nowadays, knowing that apoptosis is a gene-controlled
process makes it susceptible to therapy by genetic manipulation[124]. It is,
also, well-understood that anticancer agents induce apoptosis and that a
reduction of sensitivity to treatment can be due to disruption of apoptotic
pathways[125]. Moreover, multi-drug resistance can occur from mutations
in the same apoptotic pathways that are targeted by different anticancer
agents[126, 116]. Ferreira et al.[124] suggests that apoptotic genes and
proteins have become attractive targets for cancer treatment because of
several reasons: the growing knowledge on the apoptotic machinery, the
ability to specifically target tumour cells due to recent technological de-
velopments that enable approaches that allow the genetic modification of
cancer cells and the identification of cancer cell-specific genetic alterations,
and finally, the advances in combinatorial chemistry and screening meth-
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ods that accelerated the pace of development of inhibitors to a selected
target. However, it is still unclear how to specifically trigger apoptosis in a
cancer cell and get it to kill itself rather than force it to die directly using
a cytotoxic drug[127]. Most of the clinically used chemotherapeutic drugs
target pathways essential for growth or proliferation, such as blocking pro-
duction of DNA, mRNA, or protein, directly damaging DNA, or inhibiting
DNA replication or chromosome separation. All these drugs cause cells
to undergo mitotic catastrophe, lose the integrity of their plasma mem-
brane, or become senescent, even if their apoptotic stress response has
been disabled[128, 129, 130]. In cells where apoptotic mechanisms are still
intact, the same drugs would cause apoptosis and cell suicide[128]. And
since apoptosis is a common stress response, cells treated with these lethal
toxins will often die because of apoptosis activated by the drug rather than
its direct toxic effect[128, 131], and this frequently leads to two common
challenging outcomes of cancer drugs:
The first problem these drugs might cause is the production of a drug-
resistant cell population. At the beginning of cancer development, the
population of cancer cells has to compete for space, nutrients, and oxy-
gen and those that are most vigorous and, most importantly, lost crucial
components of the apoptosis pathways or overexpress cell death inhibitors
would have an advantage and survive in a Darwinian selection[128]. During
radiotherapy or chemotherapy, cancer cells that are genetically resistant to
apoptosis might be selected even further resulting in a cancer cell popula-
tion that is resistant to any drug that targets apoptosis and also resulting
in the second major hurdle of cancer therapy which is toxicity to normal
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cells that naturally have intact apoptosis mechanisms, making them more
sensitive to these drugs. Most treatments designed to induce apoptosis in
cancer cells also reach normal cells. According to many pathologists, these
cells might also undergo apoptosis and that usually leads to the side-effects
of cancer drugs to organs, such as bone marrow, gastrointestinal tract,
and skin, making a cancer therapy that acts merely by apoptosis induction
without causing any intrinsic cytotoxicity more likely to cause the death of
more normal cells than cancer cells. Controversially and to overcome this
problem, agents that inhibit, rather than induce, apoptosis might be used
in conjunction with toxic drugs to reduce dose-limiting side-effects due to
apoptosis of normal cells[128, 132, 133].
Alternatively, targeting tumour-specific alterations in apoptotic programs
offers the chance to target cell death in a selective fashion and less opportu-
nity for acquired drug resistance. The inhibition of Bcl-2 family members
that are overexpressed in cancer cells can be lethal to these cells and this is
a very good example for this approach. Taxanes, for instance, induce phos-
phorylation and inactivation of Bcl-2[134], and an adenovirus-mediated
gene transfer of Bcl-xS, which is a dominant-negative repressor of Bcl-2
and Bcl-xL, can synergize with chemotherapy to promote tumour regres-
sion in xenographs[128, 135, 136] but produces minimal apoptosis when
introduced into normal epithelial cells[128, 117].
Another example for altered apoptosis pathway in cancer cells that can be
targeted for treatment is TRAIL-mediated death pathways[137]. TRAIL
is a TNF-related protein that binds to its receptors DR4 or DR5 to initi-
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ate p53-independent apoptosis[128]. Normal cells are resistant to TRAIL-
induced apoptosis because they express “decoy” receptors that compete
with DR4 and DR5 for TRAIL but do not trigger any apoptosis-inducing
signal[138, 139]. Tumour cells, on the other hand and through an unknown
mechanism, seem to widely lose the expression of the decoy receptor 1,
and hence are superbly susceptible to TRAIL-mediated cell death[128]. In
recent reports, however, the role of decoy receptors for TRAIL signalling
was questioned[140, 141].
The lack of specificity of cancer treatments limits their maximum adminis-
tration dose and hence, their efficacy. In addition to previous examples and
other clinically used agents that precisely target tumour cells, the recent
emergence of the so-called anticancer genes is also significantly contributing
to the field.
1.2 Anticancer Genes
Anticancer genes are a recently defined group of genes that share spe-
cific characteristics. Defined by Grimm and Noteborn, these genes specif-
ically destroy tumour cells without harming normal cells when ectopically
overexpressed[142]. These genes induce tumour-specific cell death by trig-
gering complex signalling pathways that are changed upon cell malignant
transformation or universal signals that interfere with others that have
changed as a result of the transformation process. The signal they induce
can result in apoptosis, mitotic catastrophe followed by apoptosis or necro-
sis, or autophagic cell death. Some of these genes have already made it to
clinical trials in either a protein therapy approach, where proteins encoded
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by anticancer genes are fused to cell-penetrating peptides, or a genetic ther-
apy approach, where genes are packed into viral vectors.
Proteins encoded by these genes exert their effects when overexpressed and
consequently dominantly activate a downstream signalling pathway and
generate the relevant interactions for cell death to be followed. This can
either be a positive signal or an inhibitory signal for certain proteins and
their signalling pathways that result in tumour-specific cell destruction.
A distinction between anticancer genes and the well-established tumour
suppressor genes has to be acknowledged. Tumour suppressor genes are
genes that inhibit tumour growth at their endogenous levels. When both
alleles of these recessive genes are inactivated in cancer cells, malignant
growth is facilitated. Unlike anticancer genes, they do not act against
oncogenes at their endogenous levels and when overexpressed, for example
p53, they usually cause apoptosis both in normal and tumour cells. On
the contrary, some anticancer genes can inhibit oncogenes, on which some
cancer cells are dependent, and therefore, induce cell death. Moreover,
some data suggest that some anticancer genes can possibly act as tumour-
suppressor genes. Table 1.
Isolated anticancer genes so far:
Apoptin
Apoptin was the first isolated anticancer gene[143]. It is a chicken anaemia
virus gene that, when ectopically overexpressed, induces apoptosis in many
human cancer cell lines but not in normal cells[144]. Apoptin is selec-
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tively phosphorylated in cancer cells where it elevates the ceramide level,
which has a tumour suppressor function[145, 146, 147]. It also induces
G2/M cell cycle arrest that results in p73/PUMA-mediated apoptosis[148,
149]. This is a result of its interaction with the anaphase promoting com-
plex/cyclosome (APC/C), which is known to induce apoptosis in trans-
formed cells when downregulated[150]. Independently of p53, Apoptin in-
duces an apoptosis signal that involves cytochrome-c release and caspases
activation[149, 151, 152]. It can be activated by the expression of SV40
transforming protein domains in normal fibroblasts[153].
Brevinin-2R
This gene was isolated from the skin of the frog species Rana ridibunda and
encodes an anti-microbial 25-amino acid peptide[154]. Although not a lot
is known about Brevinin, it was shown to induce autophagy-like cell death
in transformed cells through a specific connection with endosomes[154].
E4orf4
E4orf4 is an adenoviral protein that is phosphorylated by Src kinases, which
results in cell death activation in transformed cells[155]. It also inter-
acts with the protein phosphatase 2A (PP2A) that is essential for tumour
development[156]. E4orf4 does not seem to induce apoptotic cell death in
transformed cells as no cytochrome-c release nor activation of caspases is
required for the cells to die. Instead, the cells undergo different morpho-
logical changes such as the formation of multiple nuclei and the increase in
the cell volume, indicating cell death via growth arrest, mitotic catastrophe
and necrosis[157].
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HAMLET
HAMLET encodes the milk protein α-lactalbumin, which induces cell death
in transformed cells when complexed with oleic acid[158]. HAMLET is pref-
erentially transported into transformed cells where it induces a range of sig-
nals including proteasome inhibition, mitochondria activation, ER stress,
and binding to different histones to impair transcription[159, 160, 161].
Nonetheless, cell death induced by HAMLET is an autophagic cell death
rather than apoptosis[162]. HAMLET was the target of two successful clin-
ical trials. The first clinical trial was carried out in 2004 by Gustafsson et
al. were HAMLET was topically used on skin papilloma lesions of 20 pa-
tients. The lesion volume was reduced by 75% or more in all 20 patients,
and in 88 of 92 papillomas, compared to 3 out of 20 patients in the placebo
group. During the second phase of the study patients of the placebo group
were treated with HAMLET and showed a median reduction of 82% in the
lesion volume. No adverse reactions were reported and the beneficial ef-
fect lasted for two years after the end of the second phase[163]. The second
clinical trial performed by Mossberg et al. in 2007 involved a 5 daily intrav-
esical instillations of HAMLET in nine bladder cancer patients during the
week before scheduled surgery. The group reported a rapid and HAMLET-
specific increase in the shedding of, mostly dead, tumour cells into the
urine and a reduction in tumour size or change in tumour character in 8 of
9 patients. Biopsies from the remaining tumours in 4 patients showed pos-
itive TUNEL staining whilst adjacent healthy tissue showed no evidence of
toxicity[164]. In addition to some other in vivo animal studies[165], these
results suggest promising therapeutic applications of HAMLET. Neverthe-
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less, most of these studies looked at the local administration of HAMLET.
Hence, studying the effect of the systemic administration of HAMLET in
pre-clinical trials might provide a better insight into its efficiency and speci-
ficity.
Mda-7 (IL-24)
Mda-7 encodes a secreted cytokine that modifies the immune system un-
der normal physiological conditions. When overexpressed, it is mainly lo-
calised to the Golgi and the ER where it exerts an ER stress signal[166].
Furthermore, it induces apoptosis in transformed cells by activating the
mitochondria to produce reactive oxygen species[167]. Although its speci-
ficity to tumour cells cannot be explained thus far, its broad effect to even
untransfected cells could be due to the upregulation of the endogenous
Mda-7 protein by secreted Mda-7 from neighbouring transfected cells[168].
Mda-7 has made it to phase I clinical trials of solid tumours and results
showed an excellent tolerance and a high clinical efficacy, in addition to
some resistance in subsets of tumour cells[169, 170].
Noxa
Noxa is BH3 only protein of the Bcl-2 family. Lately, it has been found to
specifically kill breast cancer cells with no harmful effect on normal mam-
mary epithelial cells[171]. The mechanism of this tumour-specific effect is,
again, not fully understood yet.
Parvovirus-H1 NS1
NS1 is a viral protein that interacts with the catalytic subunit of casein ki-
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nase II (CKIIα) to link it to the cytoskeletal filament protein tropomyosin,
a process that results in an altered pattern of tropomyocin phosphorylation.
It causes cell death in tumour cells by inducing changes in the cytoskeleton
filaments of these cells and this results in the degradation of actin fibres
and the production of actin patches[172]. It was also found to activate
phosphoinositol-dependent kinase signalling in these cells[172].
Par-4
The main feature of Par-4 protein is the presence of a leucine zipper do-
main. At its endogenous level, Par-4 is involved in several different apop-
tosis signals[173] and is reported to act as a tumour suppressor gene[174].
Its mechanism of action as an anticancer gene in tumour cells has been
explained by its interaction with Akt1, which keeps both Akt1 and Par-4
inactive. In many tumour cells, Akt1 is normally overactive, and that is
why overexpression of Par-4, which will inactivate Akt1, shows a toxic ef-
fect in tumour cells and not in normal cells[175]. ER stress and caspase-8
activation in transformed cells caused by Par-4 were also reported[176].
TRAIL
TNF-related apoptosis-inducing ligand (TRAIL) is a member of apoptosis-
inducing TNF family ligands that was shown to induce apoptosis in tumour
cells but not in normal cells[177]. It is the most advanced anticancer protein
in terms of clinical application and its mechanism of action was discussed
above. However, recent studies showed that not all primary human tumour
cells are susceptible to TRAIL-induced apoptosis and that is why combi-
nation therapy is always recommended when using TRAIL.
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ORCTL3
This is the most recently isolated anticancer gene and it is the main focus
of this project. Please see section 1.4.
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1.3 The Role of Stearoyl-CoA Destaurase-1 in Can-
cer
Stearoyl-CoA desaturase 1 (SCD-1), also known as fatty acyl-CoA delta-9
desaturase, is an ER resident enzyme that catalyses the introduction of the
first double bond in the cis-delta-9 position of many saturated fatty acyl-
CoAs (SFAs), mainly palmitoyl-CoA and stearoyl-CoA, to yield monoun-
saturated fatty acids (MUFAs), palmitoleoyl- and oleoyl-CoA, respectively
[178]. Up to four different variants of SCD exist in mammalian organ-
isms, however, only two isoforms of SCD, SCD-1 and SCD-5, have been
found in humans[179, 180, 181]. SCD-5’s expression is limited in human
tissues and its physiological function is nearly unknown[180, 181]. SCD-1,
on the other hand, is considered the main isoform and is universally ex-
pressed in human tissues with highest expression levels in the brain, liver,
heart and lungs[179]. Moreover, it was reported that this enzyme is also
highly expressed in oncogene-transformed lung fibroblasts and in cancer
cells[182, 183, 184]. In addition to cancer, SCD-1 is found to be elevated
in other metabolic diseases, such as diabetes, obesity and atherosclero-
sis, suggesting a common molecular association between these diseases and
cancer. In cancer and in all these metabolic diseases there is a dominant
metabolic shift towards biosynthetic reactions that result in the overpro-
duction of lipid for different reasons. For example, in obesity and diabetes,
affected cells overproduce lipid that is needed for energy storage such as
triacylglycerols and cholesteryl esters[185]. However, in cancer cells, the
newly produced lipids are used up in the formation of new phospholipids
for membrane biosynthesis[186]. The alterations of lipid metabolism and
the elevation of SCD-1 in cancer cells suggest an important role of SCD-1
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in cancer cell proliferation, cancer development, and perhaps apoptosis in
these cells, making it a potential target for cancer therapy.
Before cell division, cells double their membrane content in order to keep
the size/surface ratio in daughter cells[187, 188]. SCD-1 is a main regulator
of this process as it is found to be a central target for stimulation by growth
factors and hormones, such as epidermal growth factor and insulin, which
control key cell cycle events[189, 190, 191, 192]. The several fold upregula-
tion of SCD-1 in transformed cells can be explained by the high demand for
more MUFAs to cope with the high synthesis of membrane phospholipids
that are needed for the increased cellular divisions and proliferation[193].
In addition, the substantial production of SFAs in cancer cells as a result
of constitutively overexpressed fatty acid synthase (FAS) also leads to the
upregulation of SCD-1 to clear the excessive amount of SFAs to protect
cells against SFA-mediated cytotoxicity. Extra content of SFAs triggers
programmed cell death in a process known as lipid-mediated toxicity, or
lipoapoptosis[194]. Consequently, increased SCD-1 activity results in more
MUFAs production that will be used to supply the membrane biosynthesis
machinery[195]. SCD-1 was identified as a main regulator in the activation
of lipid synthesis in cancer cells because of the general significant impair-
ment in the lipid biosynthesis mechanisms that was observed in oncogene-
transformed cells and lung cancer cells in which the expression of SCD-1
was reduced by stable gene knockdown or completely blocked with a spe-
cific chemical inhibitor[182, 184, 196].
MUFA production is differentially controlled according to the metabolic
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requirements of different phases of the cell life. When cells slow down or
stop proliferation the rate of membrane phospholipids synthesis declines
and significant reduction in the activity and the expression of SCD-1, that
is also parallel to the decrease in FAS, is observed[193, 197, 198]. This is a
normal outcome from the repression of fatty acid synthesis and desatura-
tion in these cells. This adaptation step takes place for example when cells
respond to stress by undergoing apoptosis or replicative senescence (when
aging cells progressively lose their ability to divide but remain metaboli-
cally active after several rounds of mitosis). Both normal and transformed
cells showed downregulated SCD-1 activity and expression upon apoptosis
induction with proapoptotic agents or cell stressors such as etoposide, ce-
ramide and tunicamycin[193, 195].
The constantly upregulated and active SCD-1 in cancer cells is not a luxury;
it is a necessity. The abnormally increased aerobic glycolysis in malignant
cells is proposed to be an adaptation of malignant cells to intermittent hy-
poxia in pre-malignant lesions[193, 199]. Upregulation of aerobic glycolysis
in cancer cells results in an overproduction of metabolites such as citrate
and glycerol that are used for lipid synthesis. The main direct products
of glucose-derived fatty acid synthesis are SFAs. However, these abundant
SFAs are immediately converted by SCD-1 to MUFAs which are, instead,
considered to be the major end products of glucose metabolism in cancer
cells. This conversion is essential in these cells in order to uphold a con-
tinuous flux of glycolytic metabolites into the production of MUFAs and
therefore, formation of vital cellular lipids and maintaining an increased
rate of aerobic glycolysis[193].
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It is still unknown how SCD-1’s elevated activity affects tumour progres-
sion, but increased SCD-1 activity and expression have been reported in
many cancers such as, oesophageal and colonic carcinoma, hepatocarci-
noma, hepatocellular adenoma and chemically induced tumours[200, 201,
202, 203]. Moreover, studies on Oncomine reveal a high SCD-1 expres-
sion in breast, lung, renal, prostate, bladder, and colon cancer and in
leukemia[193].
The review by R.Ariel Igal in 2010 comprehensively summarises all the ret-
rospective and prospective epidemiological studies that were carried out in
an effort to link aberrations in SFAs and MUFAs levels to cancer incidence
and death[193]. In summary, studies show that unbalanced levels of SFAs
(low) and MUFAs (high) in serum, erythrocyte membranes or cholesterol
esters can positively correlate to risk of breast cancer or to a greater cancer
death rate in patients[204, 205, 206]. Moreover, higher oleic acid in adipose
tissue in women diagnosed with breast cancer was significantly associated
with lymph node metastasis, and low levels of SFAs in breast cancer were
linked to metastasis and poor prognosis[207, 208]. Furthermore, a study,
known as the EURAMIC study, that was carried out to correlate the inci-
dence of breast cancer in patients from different European countries to their
MUFA levels in adipose tissue provided a proof of a positive association of
the MUFA palmitoleic and cis-vaccenic acids with breast cancer[209]. In
addition, it showed a neutral to positive correlation between oleic acid and
breast cancer except in patients from Spain where MUFA-rich olive oil is
the primary source of oleic acid[209]. Although it was not directly proven,
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the reported elevation of SCD-1 -expression and -activity in cancer cells can
be the immediate cause for the imbalance in fatty acid species in cancer
patients[193]. The role of SCD-1 in several cancer cells was better under-
stood when genetic and pharmacological suppression of SCD-1 resulted in
slower rate of cell proliferation and induced cell death[182, 184, 196, 210],
suggesting that transformed cells require a certain level of SCD-1 activity
to evade apoptosis. Interestingly, when SCD-1 was inhibited in normal
human skin fibroblasts, these cells were resistant to the cytotoxic effect
of SCD-1 inhibition[182], suggesting that SCD-1 activity might be crucial
only in highly mitogenic cells[193]. Moreover, the effect of SCD-1 inhibition
in cancer cells suggests that SCD-1 might also play an important role in
tumour formation and progression[193]. This hypothesis was supported by
xenograft lung tumour models in mice where the cancer cells with stably
reduced levels of SCD-1 showed severely impaired capacity to form tumours
or to support progression of tumour growth[196]. Another mice study also
showed a correlation between the background level of SCD-1 expression
and the predisposition to liver carcinogenesis[211], where mice with higher
levels of SCD-1 were found to be more prone to initiation of cancer.
Finally, while there is certainly a need for a clearer picture for the under-
standing of the physiological and the biochemical functions of SCD-1 at
the molecular level, what is already known about this enzyme suggest that
targeting SCD-1 might be a novel pharmacological approach for cancer
intervention[193].
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1.4 Organic Cation Transporter Like-3 (ORCTL3)
1.4.1 Isolation of ORCTL3 as an Anticancer Gene
Organic cation transporter like-3 (ORCTL3) was isolated by Irshad et al.
in a screen for tumour-specific apoptosis-inducing genes[212]. The screen
was performed by searching for proapoptotic cDNA plasmids in the kidney
cell line HEK293T, cells that display characteristic features of tumour cells
such as tumour formation in nude mice and growth in soft agar[213]. Out
of a total of 150,000 clones representing ∼60% of one kidney cDNA library,
112 apoptosis genes were detected. These genes were then transfected
simultaneously in normal rat kidney (NRK) cells and in H-Ras-transfected
NRK cells in order to carry out the screen in a defined isogenic background.
In agreement with the known cell death inhibitory effect of H-Ras, only 44
genes from the primary screen remained active in H-Ras transformed cells
whilst more genes were still active for apoptosis induction in WT NRK cells.
Interestingly, only one clone was active for apoptosis induction in H-Ras
transformed NRK cells but not in WT NRK cells. This clone was identified
by sequencing as the full length ORCTL3/SLC22A13[212], and apoptosis
cell death was confirmed by an apoptosis-specific quantitative assay for
DNA cleavage and cell death inhibition by the pan-caspase inhibitor z-
VAD[212]. Figure 1.8.
1.4.2 Discovery and Mapping of ORCTL3
ORCTL3 was originally isolated from a large-scale DNA sequencing project
of a portion of chromosome 3p22 to p21.3, a DNA segment that is homozy-
gously deleted in a lung cancer cell line[214], performed by Nishiwaki et al.
in 1998[215]. Out of the nine genes that were identified in this 1200-kb re-
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Figure 1.8: ORCTL3 specifically induces apoptosis in H-Ras-
transformed cells compared to WT NRK cells. (A) Outline of the
screen for tumor-specific apoptosis genes. (B) Specific generation of the
apoptosis phenotype by ORCTL3 in H-Ras transformed cells. (C) Quan-
tification of the apoptosis induction by ORCTL3 in NRK WT and NRK
H-Ras cells. (D) Quantification of apoptosis by ORCTL3 with an ELISA
against DNA fragments. (E) Reduction of apoptosis by the pan-caspase
inhibitor z-VAD. (Figure adapted from Irshad et al. 2009).
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gion, ORCTL3 was detected. It was designated ORCTL3 because of its ho-
mology and similarity to proteins belonging to the family of organic cation
transporters, especially rat OCT-1r, rat NLT, mouse NKT, and a group
of sugar transporting proteins including human glucose transporters[215].
Its predicted peptide sequences are 33.9% identical to another protein that
was mapped within a very small region of genomic DNA and designated
ORCTL4; a high conservation of transporter-specific amino-acid motifs and
a possible similarity in transmembrane-domain profiles. Hence, it was pre-
dicted that ORCTL3 and ORCTL4 are likely to play some polyspecific role
in transporting organic cations in tissues[215].
Organic anions and organic cations are the hydrophilic metabolites of many
lipid-soluble compounds. These charged compounds are difficult to be
transported through the plasma membrane without transporters. Organic
anion and organic cation transporters play an important and multi-specific
role in moving these charged molecules across the plasma membrane[216].
1.4.3 Structure and Physiological Function of ORCTL3
The orphan transporter protein ORCTL3 belongs to the solute carrier fam-
ily 22 (SLC22) but has not been broadly studied yet[217]. Its gene spans
around 12-kb of genomic DNA, and consists of 10 exons. It was shown that
the 2.4kb transcript of this gene is universally expressed in all human tis-
sues with some preference for kidneys, small intestine, and colon; and this
can be justified by the active transport and secretion of substances in these
organs. The same northern blot analysis also showed, in addition to the
2.4kb transcript, a larger 2.6kb transcript that contained a longer 3’ poly
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A non-coding sequence specifically in the kidney[215]. However, another,
more recent, study that evaluated the tissue distribution of ORCTL3 by
RT-PCR suggests that ORCTL3 is a kidney-specific transport protein due
to its strong expression in the apical side of renal proximal tubule cells
in the kidney, and weaker expressions of other splice variants of the open
reading frame of ORCTL3 in other tissues such as the brain, the heart,
and the colon[217]. This study also suggests that ORCTL3 is expressed in
a gender-dependant manner with a dominant female over male expression,
which might result in gender-specific reabsorption and secretion of the sub-
strate.
The reason behind calling this gene ORCTL3 was its similarity to other
organic cation proteins when it was first isolated[215]. However, the only
study that was conducted to further understand the physiological function
of this protein proved this wrong[217].
Bahn et al. have aligned protein sequences of all known organic cation
transporters (OCTs) and organic anion transporters (OATs) and based on
comparisons to identify highly conserved amino acids, they hypothesized
that ORCTL3 is rather an organic anion transporter[217].
After examining the properties of ORCTL3, they revealed evidence that
ORCTL3 is a transporter for urate, the end product of purine metabolism,
and nicotinate, as such proposed ORCTL3 as the first identified high affin-
ity nicotinate exchanger in kidneys and intestine. Nicotinate is an essen-
tial vitamin (Vitamin B3) that is involved in NAD
+ synthesis, which is
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important for energetic processes, signal transduction pathways, and the
activation of the NAD+-dependant histone deacetylase SIRT1 and hence,
life extension[217, 218]. Therefore, ORCTL3 was instead named OAT10
(organic anion transporter 10). The study also showed an elevation of
urate reabsorption by ORCTL3 (OAT10) in a cyclosporine A-induced hy-
peruricemia. Moreover, it suggested two more substrates (counter ions) of
ORCTL3: succinate and glutathione[217]. That was the first and the only
study so far that investigated the role of endogenous ORCTL3.
ORCTL3 encodes a 551-amino acid protein[217] that shows a 90kDa band
on western blot when using an antibody against mouse ORCTL3[216]. A
hydropathy plot of the predicted polypeptide sequence of ORCTL3 per-
formed by the programme from Kyte and Doolittle indicated 10 hydropho-
bic segments suggesting that the protein spans the cell membrane several
times[219]. When the membrane topology was analysed again by Lee et
al., mouse ORCTL3 showed 12 putative transmembrane domains with both
N- and C-termini located in the intracellular space. It also showed four N-
glycosylation sites in the extracellular surface between the first and the
second membrane spanning domains, which explains the large protein size
on the western blot. In addition, mouse ORCTL3 contained six intracellu-
lar PKC phosphorylation sites[216]. Figure 1.9.
1.4.4 The Function of ORCTL3 as an Anticancer Gene
ORCTL3 is unique in its apoptosis induction activity. Irshad et al. tested
two other related gene family members of the organic cation transporter
family but both showed no toxic effect[212]. They hypothesized that OR-
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Figure 1.9: ORCTL3 protein structure showing prediction of the 12
transmembrane domains. Source: http://pharmacogenetics.ucsf.edu/cgi-
bin/Gene.py?hgncSymbol=SLC22A13
CTL3’s apoptosis induction activity is independent from its transporter
activity, because progressive deletions of the C-terminal half of the pro-
tein did not significantly disturb its apoptosis potential. ORCTL3 activity
was not limited to H-Ras activation as NRK cells transformed with v-src
were also tested for their response to ORCTL3 overexpression and results
showed that they were likewise susceptible to its apoptosis signal. Figure
1.10.
The effect of ORCTL3 was never cell line-specific as it was tested in a
number of transformed tumour cells, such as HeLa, LnCap, and PC3, and
untransformed cells such as MDCK, HUVEC, and RPT cells. ORCTL3
induced apoptosis in all tested transformed cell lines and remained inac-
tive in all tested untransformed cells. Figure 1.11. This was not due
to variations in the expression levels of overexpressed ORCTL3 protein in
different cells as measuring protein expression levels in all cells showed no
significant differences[212].
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ORCTL3 cellular distribution was studied by overlapping the signals from
an ECFP fusion protein of ORCTL3 and specific staining of organelles in
HeLa cells. The fusion protein of ORCTL3 was found in ER, Golgi and the
plasma membrane but, importantly, not in the mitochondria. The cellular
locale of ORCTL3 did not differ between WT NRK cells and H-Ras trans-
formed NRK cells. It was then speculated that ORCTL3, due to its cellular
location, exerts its apoptosis activity at the ER or Golgi. When a fusion
construct of ORCTL3 with an ER retention signal led to higher apoptosis
than wild type ORCTL3 or a fusion construct with a Golgi retention signal,
it was then hypothesized that ORCTL3 is inducing the signal for apopto-
sis at the ER. This hypothesis was further supported by the reduction of
the apoptosis signal induced by ORCTL3 when co-transfected with the ER
stress inhibitor BiP/GRP78.
After that, the upregulation of two of the ER stress factors was tested
upon ORCTL3 overexpression in transformed and normal cells. Results
indicated that transformed cells, that undergo apoptosis upon ORCTL3
overexpression, showed an upregulation of ATF4 but not BiP when com-
pared to cells treated with ER stressors: tunicamycin and ionomycin. On
the other hand, untransformed cells did not show any upregulation of either
proteins and hence, any signs of ER stress. Figure 1.12.
Finally, Irshad et al. suggested a wider role of ORCTL3 in tumouri-
genesis. This was supported by the link that was made between dele-
tions in ORCTL3’s chromosomal locus 3p21.3 and carcinomas of various
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organs[220, 221], findings that this gene is repressed in tumours of the
adrenal gland and bladder according to the Oncomine database, and fi-
nally, a blot, using Cancer Profiling Array, that compares tumour versus
normal tissues of the same patients and shows that ORCTL3 is significantly
downregulated in human renal carcinomas[212].
Figure 1.10: Characterization of cell death by ORCTL3. (A)
Structure-function analysis of ORCTL3. (B) Comparison of ORCTL3-
induced apoptosis with the effects of two other transporter molecules. (C)
Transient cotransfection of H-Ras together with ORCTL3 does not induce
apoptosis. (D) Apoptosis induction in v-src transformed NRK cells by
ORCTL3. (E) Quantification of apoptosis in v-src transformed NRK cells.
(Figure adapted from Irshad et al. 2009).
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Figure 1.11: Effect of ORCTL3 on apoptosis in transformed versus
normal cells. (Figure adapted from Irshad et al. 2009).
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Figure 1.12: ORCTL3 exerts an ER stress signal. (A) Effect of
apoptosis inhibition on the percentage of cells with apoptosis morphology
and with different degrees of internal accumulation of ORCTL3. (B) An
ORCTL3 construct with an ER retention signal (ORCTL3-ER) is more
efficient for apoptosis induction than wild type ORCTL3 or a fusion con-
struct with a Golgi retention signal (ORCTL-G). (C) BiP co-transfection
reduces apoptosis by ORCTL3. (D, E, and F) Western immunoblotting
showing the expression levels of the ER stress transcription factor ATF4
and of the chaperone protein BiP in Hela cells, HEK293T cells, or HUVEC
cells. (Figure adapted from Irshad et al. 2009).
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2 Hypotheses and Objectives
2.1 Background of the Project and Previous Results
Previous work by Irshad et al. showed that ORCTL3 induces apoptosis
through an ER stress response that causes upregulation of ATF4 in tu-
mour cells and not in normal cells. Unexpectedly, this ER stress does not
induce the upregulation of another UPR hallmark, namely BiP. It was also
shown that the ORCTL3 protein is mainly localised in the plasma mem-
brane and the ER. Moreover, deleting the seven C-terminal transmembrane
domains of the protein resulted in a construct that maintained the ability
to induce apoptosis in the cells, but that was not sufficient to make final
conclusions on the smallest functional region of the protein.
SCD-1 is an enzyme that also resides in the ER and is upregulated in
most tumours. Chemical or genetic inhibition of this enzyme induces cell
death through an ER stress in cancer cells[222]. This cell death effect was
often reversed upon exogenous supplementation of oleic acid, one of the
end product MUFAs of SCD-1[223, 182]. Moreover, the ER stress induced
by the inhibition of SCD-1 shows a very similar array of changes in the
UPR hallmarks to the ones seen upon ORCTL3 overexpression. That is,
an upregulation of ATF4, and no change to BiP level[222, 224].
2.2 Hypotheses of the Project
The co-localisation of ORCTL3 and SCD-1 in the ER, the effect they both
exert on cell death in cancer cells, and the ER stress pattern they activate
lead us to hypothesise that ORCTL3 induces its apoptosis effect through an
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interaction with, or an inhibition of, SCD-1. The positive outcome would
lead us to further hypothesise that this inhibition or its consequences are
tumour-specific. We may also debate what the mechanism is by which
ORCTL3 inhibits SCD-1, whether it occurs at all in normal cells, and
whether it is a functional inhibition of the enzymatic activity. Finally, we
may also ask what the minimal functional domain of ORCTL3 is and what
other pathways it targets.
2.3 Objectives
This project was an effort to understand the mechanism of action by which
ORCTL3 exerts its unique apoptosis effect in cancer cells. To address this
objective I will show the ORCTL3 apoptosis effect when examined in trans-
formed cells with strictly controlled genetic background to test its tumour
specificity. The ER stress induced by ORCTL3 will be studied further and
especially through its connection to lipid metabolism and the role of SCD-1
in cancer cells. I will also compare the effect of mouse ORCTL3, used in
the previously published work by Irshad et al.[212], and the effect of the
human homologue. Finally, the minimal functional domains of ORCTL3
that incorporate its apoptosis induction ability is still unknown. To facil-
itate the use of this protein in future pre-clinical or clinical applications,
mapping the protein was, likewise, one of the main motives of this work. In
general, a better molecular understanding of the unique effect of this novel
protein and its functional and structural basis, was the motive behind the
described work.
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3 Materials and Methods
3.1 Reagents and Materials
From Sigma-Aldrich
2-mercaptoethanol (M7522), 6-aminocaproic acid (A2504), acrylamide (40%
solution, A7168), agarose (A9539), ammonium persulfate (A3678), ampi-
cillin sodium salt (A9518), bovine serum albumin (BSA, A7906), calcium
chloride (C7902), dimethyl sulfoxide (D2650), Dulbeco’s modified Eagle’s
media (D6429), DMEM AQmediaTM(D0819), EDTA (E6758), fluorescein
diacetate (F7378), EGTA (E4378), fetal calf serum (F7524), hydrochloric
acid (H7020), HEPES (H3375), kanamycin (K1876), Luria-Bertani broth
(L3022), L-glutamine (G7513), McCoy’s 5A media (M8403), n-dodecyl-
β-D-maltoside (D4641), NP-40 (I3021), oleic acid-albumin from bovine
serum (O3008), phosphate buffered saline (D8537), propidium iodide so-
lution (P4864), RPMI-1640 (R5886), puromycin dihydrochloride (P8833),
skim milk powder (70166), sodium azide (S8032), sodium citrate (S1804),
sodium deoxycholate (30970), sodium pyruvate (S8636), TEMED (T9281),
Triton X-100(T8532), trypsin-EDTA(T4174), TWEEN R©(P5927), yeast ex-
tract (Y1625).
From Life Technologies
25mm blotting filter papers (LC2010), DiOC6 (D273), geneticin
R© selec-
tive antibiotic (G418 Sulfate) powder, library efficiency R© DH5αTMchem-
ocompetent bacteria (18263-012), MAX efficiency DH5α (18258-012), Oligo
(dT)20 Primer (18418-020), PureLinkTMHiPure plasmid filter purification
kit (K2100-07), penicillin/streptomycin (15070-063).
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From Thermo Fisher Scientific
In addition to all FastDigest R© restriction endonucleases: 5X protein loading
buffer (R0891), 6X DNA loading dye (R0611), 50X TAE buffer (B49), Brad-
ford reagent (500-0006), GeneRulerTM1kb DNA ladder (SM0314), Phusion R©
polymerase (F530-L), PageRulerTMprestained protein ladder(SM1811), T4
DNA ligase HC(EL0013), ProteoBlockTMprotease inhibitor cocktail(R1321).
From Bio-Rad Laboratories
0.5M Tris-HCl pH 6.8 solution (161-0799), 1.5M Tris-HCl pH 8.8 solution
(161-0798), 10x TGS buffer (161-0772), and SDS solution (10% w/v, 161-
0416).
From various suppliers
Hyper filmTMhigh performance chemoluminescent film (28906837) was pur-
chased from GE Healthcare. PureProteomeTMProtein G magnetic beads
(LSKMAGG10) and PVDF membrane (IPVH00010) were purchased from
Millipore. QuickChange II site directed mutagenesis kit (200523) was
from Agilent Technologies; sodium chloride (10241) from BDH Labora-
tory Supplies; saponin (47036) from Fluka; Wizard SV gel PCR clean-up
system (A9282) was from Promega; Effectene (301427) was from QIAGEN;
GelRedTMnucleic acid gel stain (41002) from Biotium; tryptone (0123-17-
3) was from DIFCO laboratories; LB-agar (852323) from OXOID Ltd.; en-
hanced chemoluminescent reagent (#32106) and paraformaldehyde (28908)
from PIERCE Thermo Scientific. CAY10566 (10012562) was from Cayman
Chemical. XfectTMtransfection reagent (631318) was from Clontech. Jet-
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PEI (101-10) was purchased from Polyplus Transfection.
3.2 Recipes of Commonly Used Buffers
Luria-Bertani (LB)Broth
1% Bacto tryptone, 0.5% Bacto-yeast extract, 1% NaCl. pH brought to
7.5 by adding NaOH
ORCTL3 lysis buffer
(750mM 6-aminocarporic acid, 50mM Bis-Tris) pH 7.0 by adding either
NaOH or HCl, and then adding 10% n-dodecyl-β-D-maltoside
Tris/Triton lysis buffer for ORCTL3/SCD-1 immunoprecipitation
in 293T cells
20mM Tris-HCl pH 7.4, 150mM NaCl, 0.5mM EDTA, 0.5mM EGTA and
1% triton X-100
Pierce IP lysis buffer for ORCTL3/SCD-1 immunoprecipitation
in HeLa cells
25mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40 and 5%
glycerol
Phosphate Buffered Saline (PBS)
137mM NaCl, 2.7mM KCl, 8mM NA2HPO4 and 2mM KH2PO4. pH 7.4
RIPA buffer
150mM NaCl, 1% NP-40, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS,
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50mM Tris-HCl. pH 8.0
SOC medium
2% tryptone, 0.5% yeast extract, 10mM NaCl, 10mM MgSO4, 2.5mM KCl
and 20mM glucose
TAE buffer
40 mM Tris-acetate and 1 mM EDTA at pH 8.3
TBS
50mM Tris-HCl (pH 7.4), 155mM NaCl
TE buffer
100 mM Tris-HCl (pH 7.5) and 10mM EDTA (pH 8.0)
TGS buffer
25mM Tris, 192mM Glycine and 0.1% w/v SDS
Sodium-dodecyl sulfate (Stacking gel)
4.8% polyacrylamide, 125mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% APS and
0.1%TEMED
Sodium-dodecyl sulfate (Resolving gel)
10-15% polyacrylamide, 375mM Tris-HCl pH 8.8, 0.1% SDS, 0.1% APS
and 0.05% TEMED
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3.3 Cell Culture
3.3.1 HeLa, 293T and Neuro2A
HeLa (human cervical carcinoma) cells, HEK293T (human embryonic kid-
ney) cells, and Neuro2A (mouse neuroblastoma) cells were cultured in Dul-
becco’s Modified Eagle’s Medium-AQ media (DMEM-AQmediaTM) (Sigma-
Aldrich) supplemented with 10% v/v fetal calf serum (FCS)(Sigma-Aldrich),
2mM sodium pyruvate (Sigma-Aldrich), 100U/ml penicillin and 100µg/ml
streptomycin (Life Technologies). They were maintained in a humidified
incubator at 37◦C and 5% atmospheric CO2. The specific guidelines for
routinely passaging each cell line were followed using trypsin-EDTA solu-
tion (Life Technologies) (final concentration of 0.05% in PBS).
HeLa cells stably downregulated for ATF-4, Bap31, Fis1, and Caspase8
by shRNA were maintained in the above conditions with the addition of
1µg/ml puromycin (Sigma-Aldrich) in the culture media.
3.3.2 CV-1
Normal CV1 cells (ATCC CCL-7) were maintained in Dulbecco’s Modified
Eagle’s medium-AQ media (DMEM-AQ) (Sigma-Aldrich) supplemented
with 10% FCS (Sigma-Aldrich), 2mM sodium pyruvate (Sigma-Aldrich),
and 100U/ml penicillin and 100µg/ml streptomycin (Life Technologies).
Transformed CV1 cells (CV1 Myc, H-Ras, dominant negative mutant p53
(with an inactivtaing point mutation), human papilloma virus E6, and ade-
novirus early region 1A, (E1A)) were maintained in the same DMEM-AQ
media that is supplemented with 15% FCS instead of 10% in addition to
1.5mg/ml aminoglycoside antibiotic (G418) (Life Technologies). All cells
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were kept in a humidified incubator at 37◦C and 5% atmospheric CO2. The
specific guidelines for splitting and trypsinization for each cell line were fol-
lowed.
CV1 cells were transformed by cotransfecting a β-galactosidase (β-gal) plas-
mid containing the G418 resistance gene and the oncogene of interest in a
1:10 ratio. Transfection efficiency of approximately 60% was achieved us-
ing the manufacturer’s recommended protocol of Xfect transfection reagent
(Clontech). Pools of transformed cells were then selected for their G418
resistance using 2.5mg/ml G418.
3.3.3 Caki-2
Caki-2 cells were maintained in McCoy’s 5A culture medium supplemented
with 2mM L-glutamine (sigma-Aldrich), 100U/ml penicillin, 100µg/ml strep-
tomycin (Life Technologies) and 10% FCS (sigma-Aldrich). They were kept
in the same incubation conditions as the above cells and split according to
general cell culture guidelines.
3.3.4 Primary Renal Cells
This procedure was adopted from M. J. Valente et al. PLoS one. 2011[225].
Additional materials needed for this procedure:
• From GIBCOTMInvitrogen, culturing medium contains: Dulbecco’s
modified Eagle’s medium with nutrient mixture F-12 (DMEM/F-12) sup-
plemented with 15% heat-inactivated fetal bovine serum (FBS), GlutaMAX-
ITM, 2.5µg/ml fungizone, penicillin/streptomycin (50 U/mL/50 mg/mL)
and 5µg/ml human transferrin.
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• Hank’s buffered salt solution (HBSS) without CaCl2 and MgCl2 (GIBCO).
• 0.05% Trypsin-EDTA solution.
• Freshly prepared and kept at 37◦C collagenase solution: 50 mg of
collagenase type 2, 315 U/mg (Worthington, Lakewood, NJ) was dissolved
in 25 mL non-supplemented culture medium and filter sterilized with 0.22
mm filter.
• Collagen coated flasks: 75-cm2 plastic culture flasks were coated overnight
at 37◦C with a 40 mg/mL solution of collagen G from bovine calf skin
(Biochrom AG, Berlin, Germany) in PBS.
• Sterile cell strainers with sieve sizes of 100, 70, and 40 mm (BD FalconTM,
BD Biosciences, USA).
• Freezing solution: 90% FBS and 10% dimethyl sulfoxide.
Collection and Isolation Procedure:
All human renal tissues were anonymously obtained from Imperial College
Healthcare Tissue Bank (ICHTB). ICHTB is a National Research Ethics
Service (NRES) approved, Human Tissue Act (HTA) licensed tissue bank.
The licence holder is the NHS and the licence number is 12275. ICHTB pro-
vides the access to anonymised human tissues without the need for project
specific NRES approval. The access to primary renal cells from ICHTB for
this project was approved by the Tissue Management Committee of the
ICHTB under application number R12009.
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Human kidney tissue samples were obtained from patients undergoing rad-
ical nephrectomy for renal cell carcinoma at Charing Cross Hospital in
London. Different tissue sizes were collected from areas macroscopically
identified as normal or tumorous immediately after extracting the speci-
men by an expert pathologist. Tissues were kept in separate sterile tubes
with ice-cold culture medium and transferred to the tissue culture labo-
ratory on ice where the isolation of the cells took place within an hour
of collecting the tissue. Isolation of renal cells was performed in a tissue
culture flow hood and under sterile conditions and extra care was taken
to avoid any possible cross-contamination between normal and tumour tis-
sues. The isolation procedure started by first transferring the tissue to a
60-mm Petri dish and dissecting off the fibrous capsule from the normal
tissue and any fat, blood clots and connective tissues from tumour tissues.
Using scalpels, the tissues then were cut into small pieces, transferred to
a sterile 50ml tube, and rinsed vigorously with ice-cold HBSS. The super-
natant was decanted and the washing step was repeated until the solution
was clear of blood. The tissue fragments were then transferred again to a
60-mm Petri dish and finely minced into approximately 1-mm3 pieces. The
small fragments were resuspended in 25ml pre-warmed non-supplemented
culture medium that was then combined with the 25ml collagenase solu-
tion (1mg/ml final concentration). The mixture was then incubated for
30 minutes at 37◦C with interval mixing. The digested tissue was passed
through a 100µm sieve (to remove any undigested fibrous tissues) into a
50ml centrifuge tube and then through 70 and 40µm sieves (to remove
contaminating tubular fragments and glomeruli, respectively). The sieved
cells were then washed by centrifugation at 400g for 5 minutes at 4◦C and
79
resuspending the pellet in HBSS. This step was repeated twice and then the
cell pellet was resuspended in supplemented culture medium. The isolated
cells were seeded on collagen-coated culture flask or plate and incubated in
a 95% humidified atmosphere, 5% CO2 at 37
◦C. The medium was changed
after 24 and at 48 hours intervals thereafter. When the cells had reached
80% confluence, they were either subcultured using commonly used sub-
culturing protocols, seeded for downstream experiments, or frozen using
above freezing medium.
3.4 DNA Constructs
All used mammalian expression plasmids were cloned into pcDNA3∆ vec-
tor (a pcDNA3 derivate (Invitrogen) that lacks the neomycin resistance
cassette) unless otherwise stated.
The mouse wild type ORCTL3 and ER fusion construct of ORCTL3 have
been described[212]. Deletion mutants were generated using suitable primers
and Phusion R© High-Fidelity DNA Polymerase (Finnzymes). PCR prod-
ucts were subcloned into pcDNA3∆ and fused to a hemagglutinin epi-
tope tag (HA-tag) (amino acid sequence: YPYDVPDYASLGGP) at the
C-terminal ends either by conventional restriction digestion and subse-
quent ligation using T4 DNA ligase (Promega) or by using PCR Cloning,
In-FusionTMAdvantage Kit (Clontech Laboratories, Inc.). All subcloning
products were sequenced to verify the correct sequence and transformed
into DH5α bacteria (Library Efficient from Life Technologies) according
to standard molecular biology guidelines. Plasmid DNA was then isolated
using Invitrogen maxi-prep kit according to the manufacturer’s instruc-
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tions. Human ORCTL3 cDNA was obtained from OriGene Technologies,
Inc. It was subcloned into the expression vector pcDNA3 and tagged with
HA-tag at the C-terminus using suitable primers and PCR Cloning, In-
FusionTMAdvantage Kit (Clontech).
Domain swapping was done using recombinant PCR by amplifying the
domain from the donor DNA using suitable primers with additional se-
quences at the ends to add identical sequences to both ends of the domain
that match the recipient DNA sequences that flank the recipient domain
and Phusion R© High-Fidelity DNA Polymerase (Finnzymes). PCR prod-
uct was then purified using Wizard SV Gel and PCR Clean up system
(Promega) and used as megaprimers in a subsequent PCR to amplify re-
cipient DNA and swap the domain of interest with the donor domain from
the megaprimers at the same time. The PCR product was then treated
with Dpn I to digest methylated and hemimethylated parental DNA and
purified. Sequencing, transformation and DNA plasmid isolation were per-
formed as mentioned above. Figure 3.1.
Figure 3.1: Cloning sites of deletion constructs cloned in pcDNA3∆
3.5 Bacteria Transformation
Library efficient DH5α E.Coli bacteria (Life Technologies) were used to
transform DNA plasmids. A bacterial aliquot was thawed on ice and the
DNA plasmid was added to the cells. After 30 minutes incubation on ice,
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the cells were heat-shocked for 45 seconds at 42◦C and immediately placed
on ice for 2 minutes. 1ml of SOC medium (2% trypton, 0.5% yeast extract,
10mM NaCl, 10mM MgSO4, 2.5mM KCl, 20mM glucose) was then added
to the cells and transformed cells were incubated for 1 hour at 37◦C whilst
shaking to allow bacteria to express the resistance gene (Ampicillin in most
cases). Transformed cells were then either cultured in Luria-Bertani (LB)
medium supplemented with the appropriate antibiotics (e.g. 100µg/ml
Ampicillin) or plated onto LB agar supplemented with the appropriate
antibiotics and cultured at 37◦C overnight.
3.6 Plasmid DNA Extraction and Purification from
Bacteria
Plasmid DNA was extracted from transformed bacteria using either miniprep
or maxiprerp procedures. Minipreps were performed for bacteria grown in
3ml LB media plus 10g/l yeast extract (Sigma-Aldrich) and appropriate an-
tibiotics overnight in a shaking incubator at 37◦C using the recommended
protocol of QIAprep Spin MiniPrep Kit (Qiagen). Maxipreps were carried
out using the recommended protocol of the Plasmid Maxi Prep Kit (Qi-
agen) or the PureLinkTMHiPure plasmid filter purification kit (Life Tech-
nologies) using 200ml of bacterial growth.
Concentration and purity of resulting DNA were measured using NanoDrop
(Thermo Fisher Scientific).
82
3.7 DNA Plasmids Transfections
HeLa cells were transfected with either Effectene (Qiagen) or JetPEI (Pe-
qlab) according to the manufacturer’s instructions. Effectene: for a 24-well
plate, 200ng of the DNA, 1.6µl of the enhancer, and 2.5µl of Effectene were
used. For a 6-well plate, 400ng of the DNA, 3.2µl of the enhancer, and 5µl
of Effectene were used. Cells were always washed after 5 hrs.
JetPEI: for a 24-well plate, cells were kept in 400µl complete medium and
transfected with 1µg of DNA and 2µl of transfection polymer. They were
then washed 5 hrs post transfection.
CV1, 293T, Neuro2A cells were transfected using Xfect (Clontech) accord-
ing to the manufacturer’s instructions. For a 24-well plate, 1µg of the
DNA plasmid and 0.3µg of the transfection polymer were used. For a 6-
well plate, 7.5µg of DNA and 2.25µl of transfection polymer were used.
Cells were washed 5 hours post transfection. In the case of GFP cotrans-
fection a total of 1.3µg of DNA plasmid was used instead.
Transformed CV1 cells were transfected using the same protocol but were
not washed after transfection.
3.8 Production of Stable Knockdown Cell Lines
All shRNA constructs were purchased from Life Technologies. Cell lines
were seeded in 6-well plates 24 hours prior to transfection. They were
then transfected the next day with shRNA plasmid and scramble shRNA
plasmid as a negative control. 72-96 hours post transfection, the cul-
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ture medium was replaced with a medium that contains an antibiotic
(puromycin) for selection (concentrations vary according to cell type, con-
centration for HeLa cells was 2µg/ml). Cells were cultivated for a few days
until selection was complete. They were then expanded and maintained
in lower concentrations of antibiotic (1µg/ml of puromycin for HeLa cells)
to retain the resistance and the knockdown of the gene of interest. The
downregulation of the gene was always confirmed by western blotting.
3.9 Apoptosis Quantification Assays
3.9.1 DiOC6/PI Staining of Mitochondrial Transmembrane Po-
tential and Plasma Membrane Integrity
Apoptosis in HeLa, 293T, Neuro2A, and Caki-2 cells was quantified using
3,3’-dihexylocarbocyanine iodide (DiOC6)/propidium iodide (PI) double
staining and flow cytometry analysis. Transfected cells were harvested
and incubated with 50nM DiOC6 and 5mg/ml PI for 30 minutes at 37
◦C
and another 30 minutes at room temperature to evaluate the mitochondrial
transmembrane potential. The mitochondrial transmembrane potential de-
creases with the cells’ commitment to apoptosis and DiOC6 stains living
cells with intact mitochondrial membrane while PI stains apoptotic cells.
Cell populations were defined using the forward and side scatters. FL1 and
FL2 were used to acquire DiOC6 and PI signals, respectively. Subsequent
analysis was performed using FlowJo 7.25 (Stanford University, USA).
3.9.2 Fluorescein Diacetate Staining of Viable Cells
Cell death in normal and transformed CV1 cells was indirectly quantified
by assessing cell viability through quantifying the presence of cytoplasmic
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esterases. In this assay cellular esterases cleave moieties from the lipid sol-
uble nonfluorescent fluorescein diacetate (FDA) probe to give a fluorescent
product that is charged and retained within the cell membrane if its func-
tion is still intact, leaving viable cells bright and nonviable cells dim[226].
Harvested cells were resuspended in 200µl of 2µg/ml FDA (Sigma-Aldrich)
in PBS. 2µg/ml FDA was prepared in PBS from a stock of 1mg/ml FDA
in acetone. Cells were mixed, incubated for 15 min at 37◦C, and analysed
on flow cytometer with excitation at 488nm using FL1 channel.
3.9.3 Counting to Quantify Apoptosis by Morphology
Apoptosis in normal CV1 and transformed CV1 was determined by phe-
notype quantification. It was performed by co-transfecting a green fluores-
cence protein (GFP) plasmid with the plasmid of interest at a ratio of 1:4.
Apoptosis was then quantified by determining the ratio of transfected cells
(GFP positive) and apoptotic cells (showing volume loss, chromatin con-
densation and/or membrane blebbing) in relation to all transfected (GFP
positive) cells. At least 400 cells were counted in each independent experi-
ment.
3.10 Immunostaining
Transfected cells were harvested and fixed with 2% paraformaldehyde for
30 minutes at room temperature. Cells were then washed with 3% BSA,
0.03% Saponin in PBS solution for blocking and permeabilization. 1µg/ml
primary antibody in BSA/Saponin PBS was added to the cells and incu-
bated for 30 minutes at room temperature. Cells were then washed with
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BSA/Saponin PBS. Alexa488 conjugated secondary antibody diluted 1:500
in BSA/Saponin PBS was added to the cells and incubated for 30 minutes
in the dark. Alternatively, cells were stained with fluorescein labeled pri-
mary antibody and staining was done in only one step. Cells were washed,
resuspended in BSA/Saponin PBS and placed on ice until analysing sam-
ples with flow cytometry. Alexa488 signal was detected by FL1.
Labeled primary antibody used:
Antibody against HA: HA.11 Clone 16B12 Monoclonal Antibody, Alexa
Fluor R© Labeled. Catalogue number: A488-101L (Covance).
Labeled secondary antibodies used:
Antibody against mouse IgG (H+L): Goat Alexa Fluor R© 488. A11001
(Invitrogen).
Antibody against rabbit IgG (H+L): Goat Alexa Fluor R© 488. A11008
(Invitrogen).
3.11 Protein Extraction and Quantification
For ORCTL3: Whole cell lysates were isolated using a lysis buffer that
was used originally to extract mitochondrial proteins[227]. The buffer con-
sists of 750mM 6-aminocaproic acid, 50mM Bis-tris pH 7.0, and 1.5% final
concentration of n-dodecyl-b-D-maltoside (Sigma-Aldrich) supplemented
with proteases inhibitors (Complete Mini, Roche). Cells resuspended in
lysis buffer were incubated for an hour on ice, centrifuged at 20,000 rpm
(30,000xg) for 30 minutes and the supernatant was collected.
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Since ORCTL3 protein is N-glycosyated at four different sites, deglyco-
sylation of the protein before loading was necessary for correct protein
migration. Enzymatic deglycosylation was performed using peptide N-
glycosidase F (PNGase F, New England BioLabs) and following the man-
ufacturer’s recommended protocol. Isolated proteins were denatured at
100◦C in the provided glycoprotein denaturing buffer for 10 minutes. The
denatured proteins were then incubated for 1 hour at 37◦C in 1X G7 re-
action buffer, 1% NP-40 and 1000U of PNGase F in 40µl total reaction
volume.
For all other proteins: Cell pellets were resuspended in 100 µl RIPA buffer
supplemented with proteases inhibitors (Thermo Fisher Scientific) and in-
cubated on ice for 30 minutes. The whole cell lysate was then centrifuged
at 13,300 rpm (17,000xg) for 30 minutes at 4◦C. The supernatant contain-
ing the protein lysate was collected. Cell pellets used for ORCTL3/SCD-1
immunoprecipitation were lysed in Tris/Triton or Pierce IP lysis buffer de-
scribed above.
Protein concentration was always measured using either the Bradford pro-
tein assay reagent (Bio-Rad) or BCA protein assay kit (Sigma-Aldrich)
according to each reagent’s manufacturer’s guidelines and differences in
protein concentration of lysates were adjusted to reach equal loading in
each gel.
Required volumes of protein lysates were diluted in 5X loading buffer
(Thermo Fisher Scientific) containing: 0.005% bromophenol blue as loading
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dye, 5% β-mercaptoethanol (Sigma-Aldrich) as a reducing agent, 10% SDS
as a denaturing agent, 45% glycerol for loading, and 0.5M Tris buffer).
Samples were then kept to boil at 100◦C for 10 min to ensure complete
denaturation of the proteins. Samples at this stage were ready for loading.
3.12 Western Blotting using Sodium Dodecyl Sul-
phate Polyacrylamide Gel Electrophoresis (SDS-
PAGE)
Samples of calculated volumes of protein lysates (equal concentrations)
and a pre-stained protein ladder (PageRulerTM) (Thermo Fisher Scientific)
were loaded and separated in 10 or 12% SDS-PAGE gel (made of stack-
ing gel: 4.8% polyacrylamide, 125mM Tris-HCl pH6.8, 0.1% SDS, 0.1%
APS, 0.1% TEMED and resolving gel: 10-12% polyacrylamide, 375mM
Tris-HCl pH 8.8, 0.1% SDS, 0.1% APS, 0.05% TEMED) in TGS running
buffer (25mM Tris-HCl, 192mM Glycine, 0.1% w/v SDS) at 80-120 volt.
Proteins were then transferred by semi-dry electroblotting (Bio-Rad) onto
polyvinylidene difluoride (PVDF) membrane (Millipore) in a transfer buffer
(20% methanol in TGS buffer) at a constant 200mA with varying voltage
for 1 hour. Membranes were blocked with either 3% BSA in PBS con-
taining 0.1% Tween-20 (Sigma-Aldrich) (PBS-Tween) or 5% dry skimmed
milk (Sigma-Aldrich) in PBS-Tween and then incubated with the primary
antibody for at least an hour at room temperature and up to overnight
at 4◦C. Membranes were then washed three times with PBS-Tween and
incubated with horseradish peroxidase conjugated secondary antibody for
1 hour at room temperature. After three washes, the reaction was devel-
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oped by enhanced chemiluminescence reagents (Millipore) and the signal
was developed onto photographic films (Amersham).
3.13 Co-Immunoprecipitation
At least four transfected wells of a 6-well plate are harvested using trypsin.
After washing the cells twice with PBS, 293T and HeLa cells were lysed in
500µl of either Tris/Triton buffer or Pierce IP buffer, respectively, plus pro-
tease inhibitors whilst kept on ice for an hour. Cell lysates were then spun
down at maximum speed for 30 minutes to remove cell debris. The next
step was pre-clearing: in two tubes per sample, 40µl of protein G magnetic
beads (Millipore) were equilibrated in 1ml of the lysing buffer (with pro-
tease inhibitors). Protein G magnetic beads were used to efficiently bind
immunoglobulins to capture the antibody-labeled protein of interest. Using
a special magnetic rack, the beads were pulled to the wall of the tubes and
the washing/lysing buffer was removed. The 500µl of the protein lysate
were added to the beads and the mixture was left rotating on the spinning
wheel for 20 minutes at 4◦C. Using the magnetic rack again to keep the
magnetic beads in the tubes, the supernatant was transferred to a fresh
tube. The supernatant was then split into three parts: 200µl for pulling
down, 200µl for negative control and 20 µl as input, which was stored at
this stage at -20◦C until loading. To the “pulling down” tube, 5-80µl of
the antibody against the protein needed to be pulled down was added. No
antibody was added to the negative control tube. Tubes were left spinning
on the spinning wheel overnight at 4◦C. Next day, 60µl of magnetic beads
were equilibrated in two tubes. The antibody pull down mixture and the
negative control were transferred to the beads and mixed by spinning for 2
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hours at 4◦C. Using the magnetic rack, the supernatant was discarded and
the beads attached to the antibody that is bound to the protein were kept.
The beads were then washed three times with 1ml of the buffer used to lyse
the cells, spun for 5 minutes, and the supernatant was removed using the
magnetic rack. 50-100µl of 5X loading buffer was added to the beads. The
mixture could be stored at -20◦C at this stage. Before loading the sam-
ples on the SDS-PAGE gel, they were boiled for 10 minutes and samples
then were placed on the magnetic rack. The supernatants with no beads
were loaded carefully on the gel. For the following steps of transferring,
blocking, probing, and developing, the same procedure for normal western
blotting was followed.
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3.14 Colorimetric Methylthiazol Tetrazolium (MTT)
Assay
The MTT assay was performed to determine the proliferation rates of un-
transformed and transformed CV1 cells. Cells were cultured in a 96-well
plate at a density of 5x103 cells/well in 100µl complete, phenol red free-
DMEM (Sigma-Aldrich). Cell proliferation was then assessed as follows:
20µl of 5mg/ml MTT solution (Sigma-Aldrich) in PBS was added to each
well and incubated for 3.5 hours. The MTT solution was then replaced with
150µl of 4mM HCl, 0.1% NP-40 (Sigma-Aldrich) in isopropanol. After mix-
ing by orbital shaking at 700 rpm for 15 minutes at room temperature, the
optical density at 590nm was measured with a microplate reader (FLU-
Ostar optima). The blank OD (treated wells without cells) was subtracted
from all raw absorbance data. Data were presented as the relative mean
proliferation, defined as the OD of consecutive time points normalised to
the first time point. Each time point was performed in triplicates. Statis-
tical analyses were performed using the paired one-tailed Student’s t-test
(Prism 5.0). A value of less than 0.05 was considered to be a statistically
significant difference.
3.15 Plate Clonogenic Assay
The clonogenic assay was performed to evaluate the proliferative ability
and tumourigenicity of a single normal or transformed CV1 cell. 1x104
cells were seeded into three wells of a 6-well plate and cultured in com-
plete DMEM for nine weeks to allow colony formation. Colonies were fixed
with 100% methanol and stained with 0.2% crystal violet (Sigma-Aldrich)
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in PBS. Left drying overnight, the crystal violet stain was dissolved in
10% acetic acid (Sigma-Aldrich) in distilled water. Triplicate samples were
quantified using a microplate reader at a wavelength of 590nm. Statisti-
cal analysis was performed with a paired Student’s t-test for comparison
between CV1 and CV1 transformed cells (Prism 5.0).
3.16 Cell Cycle and Proliferation Analysis Using Pro-
pidium Iodide
Cell cycle analysis was performed by flow cytometry using a fluorescence-
activated cell sorting (FACS) Calibur and propidium iodide (PI) staining.
Cells were seeded at a density of 20x103 cells per well in 24well plates
and cultured for 72 hours in complete DMEM. Cells were then trypsinised
and combined with cell culture supernatant containing non-adherent cells.
They were then spun down, resuspended in 150µl PBS with an equal volume
of 2X PI lysis buffer (20 µg/ml propidium iodide (Sigma-Aldrich), 0.1%
sodium citrate (Sigma-Aldrich), 0.1% triton (Sigma-Aldrich) in PBS), and
incubated in the dark at room temperature. The fluorescent signal was then
detected through FL2 channel and the cell cycle distribution was analysed
using the cell cycle platform in Flowjo 7.6.2 software. Cell cycle distribution
was shown as subG1, G1, S, G2/M phase percentages. For proliferation
analysis, FACS data were analysed using the cell proliferation platform in
Flowjo 7.6.2 software. The cell proliferation index was quantified by the
percentage of division (%Divided). Statistical analysis was performed with
Student’s t-test using Prism 5.0 (p < 0.05).
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3.17 RT-PCR
3.17.1 RNA Isolation
RNA was isolated from cell pellets using the recommended protocol of the
RNeasy Mini Kit (Qiagen). RNA was then treated with DNase I (Sigma-
Aldrich) for 15 minutes at room temperature to remove contaminating
DNA. The DNase I was then inactivated by heating with the stop solution.
3.17.2 Reverse Transcription
Reverse transcription of the RNA was performed using SuperScript R© III
Reverse Transcriptase (Life Technologies) and Oligo(dT)20 Primer (Life
Technologies) according to the manufacturer’s recommended protocol and
starting with the maximum volume of RNA in each reaction. Resulting
cDNA was then measured using Nanodrop and used in subsequent PCR.
3.17.3 Polymerase Chain Reaction
Equal amounts of synthesized cDNA were amplified with polymerase chain
reaction using the recommended protocol of Phusion R© High-Fidelity DNA
Polymerase (Finnzymes) and the corresponding primer sets for each target.
Annealing temperature for each reaction was calculated according to the
melting temperatures of each primer set. Table 3. For all cDNAs, βactin
was amplified in a separate tube as an external control. PCR products
were then loaded and separated using agarose gel electrophoresis.
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3.18 DNA Electropheresis
DNA separation was performed using agarose gel electrophoresis. 1-3.5%
w/v agarose (Sigma-Aldrich) was dissolved in 1X TAE buffer (Thermo
Fisher Scientific) in the presence of GelRedTMnucleic acid stain (Biotium)
at 1:10,000 dilution and left to solidify in the gel cassette at room tem-
perature. DNA samples, mixed with 6X DNA loading dye (Thermo Fisher
Scientific), and DNA Ladder (GeneRulerTM1kb) (Thermo Fisher Scientific)
were loaded in the gel and separated in TAE buffer. Separated DNA bands
were then visualised using UV lamp.
3.19 Adenoviral Infection
Adenoviruses were constructed and produced by Welgen, Inc.
Three different adenoviral particles were used in total: a virus that con-
tains ORCTL3-ER cDNA, Luciferase as a negative control, and GFP as an
infection efficiency control.
Cells were plated at low density (around 20X103 cells/well of 24 well plate)
and cultured overnight. On the day of infection, one representative well was
trypsinised and cells were counted. Viruses at an original concentration of
1X1012 virions/ml were diluted in 2% FCS DMEM to obtain the required
multiplicity of infection (MOI) for each experiment, which is a term that
refers to the number of virions that are added per cell during infection.
200ml of virus-containing -medium with the required MOI was added to
the cells and cells were incubated with the virus for 7 hours. After 7 hours
the cells were washed and kept in 10% DMEM overnight or until results
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were quantified and analysed.
Cells lacking the coxsackievirus and adenovirus receptor (CAR), such as
primary renal carcinoma cells, were infected with adenovirus with the help
of a commercially available kit, the AdBooster (Vector Biolabs). Follow-
ing the recommended guidelines of the kit, the appropriate amount of the
adenovirus was incubated with the recommended amount of the reagent in
2% FCS medium for 30 minutes at room temperature on a rotating wheel.
The virus then was added to the cells and the same procedure of the viral
infection above was followed.
3.20 Densitometry Analysis
Using ImageJ programme, a scanned image of a western blot was uploaded
and converted to 8-bit image (image → type → 8-bit). After inverting the
image (Edit → invert), the appropriate fields were selected using “rectan-
gular selection” tool and plot profile was created (analyse → plot profile).
The background intensities were subtracted by drawing a straight line (by
pressing the “shift” key during line drawing) and the distinctive peaks were
separated using “straight line selection”. When selecting the appropriate
area with “wand tool” followed by measurement (analyse→ measure), the
intensities of the bands were analysed
3.21 Statistical Analysis
Statistical analysis was carried out using unpaired, two-tailed student’s
t-test calculated by either Microsoft Office Excel 2010 or Prism 5.0.
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4 Results
4.1 Specific transformation changes caused by single
tumourigenic mutations in normal cells can acti-
vate ORCTL3 for apoptosis induction
ORCTL3 was first isolated as a tumour specific apoptosis inducer gene in
an established kidney transformation system; first in HEK293T and subse-
quently in NRK and H-Ras-transformed NRK cells[212]. To keep the work
focused on a similar kidney model, the primate renal CV1 fibroblast cells
were carefully chosen to develop a unique set of transformed cells where
only one tumourigenic mutation was introduced to the cells. The main
advantage of this approach is to enable testing ORCTL3’s tumour speci-
ficity in the most stringent manner where the normal and the transformed
cells maintain an isogenic background except for the introduced mutation.
The CV1 cell line was established in 1964 by Jensen et al. from a kidney
tissue section removed from a normal African green monkey[228]. At that
time, normal CV1 cells could be transformed by the cancer-causing Rous
sarcoma virus (RSV), and since then it has been a very useful cell line
for AIDS research and transfection and transformation experiments with
simian virus 40 (SV40), which resulted in the development of the trans-
formed COS-1, COS-3, and COS-7 cell lines by Y. Gluzman in 1981[229].
I transformed CV1 cells by introducing three individual genetic changes
that are known to be relevant for human kidney cancers. These changes
were introduced by transfecting normal CV1 with the oncogene Myc, ac-
tivated alleles of H-Ras with Gly12Val mutation and p53 which acts as a
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dominant-negative mutant of the endogenous p53 tetramer[230, 231, 232].
Moreover, the cells were also transformed by transfecting the viral onco-
genes HPV-E6, which transforms the cells by binding to and inactivating
p53[233] , and adenovirus E1A gene, which immortalizes primary cells by
interacting with Rb protein[234]. In order to mimic the tumours’ known
genetic heterogeneity[235, 236] and to avoid introducing a bias by picking
individual colonies, I used pools of transfected cells with a variety of onco-
gene expression levels. These pools of transformed cells showed a range of
morphological changes. Some of these changes have been reported previ-
ously when inducing transformation to the cells in culture, such as ruﬄed
cell edges, formation of elongated processes, presence of cytoplasmic vac-
uoles, loss of contact inhibition, increased occurrence of mitotic cells, and
the variations in the cells’ sizes[234, 237]. These morphological changes
were seen more profoundly in some cells, such as H-Ras and Myc trans-
formed cells, than the others, such as E1A expressing cells, which mostly
resembled the wild type (WT) CV1 cells. Figure 4.1A. Nevertheless,
all tumourigenic mutations led to immortalisation of the cells, while the
parental CV1 cells cease proliferation after about 10 passages. The over-
expression of the oncogenes was confirmed by detecting the level of the
different oncogenes in whole cell lysates from the pools of the transformed
cells. Figure 4.1B.
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Figure 4.1: Transformation of normal renal CV1 cells using indi-
vidual tumourogenic mutations. (A) CV1 cells were transfected with
activated alleles of H-Ras and Myc, a dominant negative mutant allele of
p53, and the viral oncogenes; E6 and E1A along with a β-galactosidase
(β-gal) plasmid containing the resistant gene for G418 antibiotic in a 1(β-
gal):9(oncogene) ratio. Cells were transfected using Xfect transfection
reagent and pools of transfected cells were selected using 2.5mg/ml G418
48hrs post-transfection for approximately 2 weeks. Cells were then cul-
tured in 1.5mg/ml G418 and 15% FCS for maintenance. Light microscopy
pictures show the morphological changes in transformed cells compared to
normal CV1 cells. (B) Two weeks after selection, an aliquot of cells from
each selection was harvested and lysed. Total cell lysates were separated
on SDS-PAGE gel and compared to an equal amount of proteins from nor-
mal CV1 cells for the overexpression of each specific oncogene using the
appropriate antibodies. β-actin was used as a loading control.
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The integrity of the apoptosis signalling pathways in the WT CV1 cells
was confirmed by testing the cells’ responsiveness to the transfection of a
number of known pro-apoptotic genes such as caspase-2, caspase-8, ANT1,
and RIP1. Figure 4.2A shows an efficient apoptosis induction caused
by these genes which confirmed the suitability of these cells to be used in
subsequent cell death experiments. The morphological changes associated
with apoptosis could be seen in the transfected cells and are shown in the
pictures taken by light microscopy in Figure 4.2B.
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Figure 4.2: Normal CV1 undergo apoptosis when transfected with
pro-apoptotic genes indicating the integrity of apoptosis path-
ways in these cells. (A) Wild type CV1 show significant sensitivity to
known pro-apoptotic genes. CV1 cells were co-transfected with a plasmid
expressing GFP and other plasmids expressing known pro-apoptotic genes
in a 1:3.3 ratio in a 24 well plate. 24 hours after transfection with Xfect
transfection kit, pictures representing the entire well area were taken and
all GFP positive cells were counted. Green cells showing morphological
changes specific for apoptosis such as cytoplasm shrinkage or/and mem-
brane blebbing were considered apoptotic and the number of apoptotic
cells compared to the total number of transfected cells represents the fi-
nal percentage of apoptosis in each well. At least 1000 cells per well were
counted for each experiment. Apoptosis induction was compared to the
background level of apoptosis in cells transfected with GFP only. Data are
presented as means ± SD of three independent experiments (n=3). **p <
0.01, ***p < 0.001. (B) Apoptosis assessment by morphological changes
of the cells using phase contrast (upper row) and UV light (lower row)
microscopy. WT CV1 co-transfected with GFP and known proapoptotic
genes; Caspase 2, Caspase 8, ANT1, and RIP in a 1:3.3 ratio. GFP plas-
mid was also transfected to assess transfection efficiency and as a negative
control. Transfection efficiency was estimated to be 60%. All proapop-
totic genes show cells undergoing apoptosis that can be easily identified by
apoptosis-specific morphological changes such as cytoplasm shrinkage and
membrane blebbing.
The effect of the tumour-specific apoptosis-inducing gene ORCTL3 was
tested in the WT CV1 and, in parallel, the transformed CV1 cells. All
cells were transfected with plasmids expressing ORCTL3 or a fusion con-
struct of ORCTL3 with an ER retention signal (ORCTL3ER), which was
described by Irshad et al. to induce more efficient apoptosis than the WT
ORCTL3[212]. In addition to these two constructs, expression constructs
of luciferase and caspase2 were transfected in parallel as a negative and
positive control, respectively. Neither ORCTL3 nor ORCTL3ER induced
noticeable apoptosis in WT CV1 cells, whilst the significant apoptosis in-
duced by the positive control caspase-2 confirmed the apoptosis sensitivity
of these cells. On the other hand, ORCTL3 induced significant level of
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apoptosis when transfected in all transformed CV1 cells that were trans-
formed by the introduction of only one tumourigenic mutation with the ex-
ception of E1A transfected cells, which showed the minimal morphological
changes compared to other transformed cells. ORCTL3ER did not induce
more apoptosis than ORCTL3 in these cells. Figure 4.3A. The reduced
apoptosis effect of caspase-2 in H-Ras transformed cells can be explained
by the known apoptosis inhibiting activity of this oncogene[238]. A lower
expression of ORCTL3 in WT CV1 cells cannot be blamed for the lack
of apoptosis induction because, on the contrary, general transfection effi-
ciency and therefore the expression level of ORCTL3 is significantly higher
in WT CV1 cells than in their transformed counterparts. Figures 4.3B,C.
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Figure 4.3: Transformation by individual oncogenes activates OR-
CTL3 for apoptosis induction in CV1 cells whilst wild type cells
remain unaffected by ORCTL3 overexpression. (A) Wild type CV1
and their transformed counterparts were co-transfected with a 1:3.3 ratio of
GFP and Luciferase as a negative control, a plasmid expressing ORCTL3,
ORCTL3 with an ER retention signal, or a plasmid expressing capsase2
as a positive control in a 24 well plate. 24 hours after transfection, pic-
tures covering the entire area of the wells were taken and apoptotic cells
were counted. At least 500 cells were counted per well. The percentage
of morphologically apoptotic cells was determined by calculating all GFP-
positive (transfected) and apoptotic cells and comparing the number to all
GFP-positive (transfected) cells in each well. Each data point represents
the mean of three independent experiments ± standard deviation (n=3).
Cells were transfected using Xfect transfection kit. Transfection mixture
was replaced by complete medium 4 hours after transfection for WT CV1
but kept unchanged in transformed cells. ***p value< 0.001. (B) Trans-
fected WT and transformed CV1 cells were immunostained with a labelled
antibody against HA tag to assess the efficiency of the expression of the
transfected ORCTL3 plasmid in all cells 24 hours post-transfection. Bars
represent the means ± SDs of the percentages of HA-positive cells from at
least two independent experiments where each sample was processed in du-
plicate, (n=4-6). ***p value<0.001 when compared to CV1 cells. (C) To
evaluate the transfection efficiencies produced by the transfection reagent
Xfect in WT and transformed CV1 cells, cells transfected with a plasmid
expressing GFP were harvested and passed through the FL1 channel in the
flow cytometry instrument. Positive signal was compared to the autofluo-
rescence emitted by each cell type. Blotted data are the means ± SDs of
at least two independent experiments where each sample was processed in
duplicate, (n=4-6). ***p value<0.001 when compared to WT CV1 cells.
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4.2 ORCTL3 does not target increased proliferation
in transformed CV1 cells for apoptosis induction
The proliferation rate of WT and transformed CV1 cells was assessed by
different means. An MTT assay revealed that all transformed cells prolif-
erate at a rate that is slightly slower than the WT CV1 cells except for
Myc-transformed cells, which showed a proliferation rate that is slightly
faster than the normal cells. Figure 4.4A. The proliferation index cal-
culated by cell cycle analysis of the cells using propidium iodide staining
also confirmed the MTT results and revealed no differences in the prolif-
eration rates of the cells. Figure 4.4B. A calculation of the percentage
of the cells that divided at least once showed a reduction of these cells
in the transformed CV1 cells compared to the WT cells. Figure 4.4C.
This can be explained by the differences of the cell populations seen in
different phases of the cell cycle. Figures 4.4D,E show a reduction of the
cell population in G1 phase and an increase in subG1 population for all
cells with tumourigenic mutations, except for E1A, which indicates that
some cells underwent apoptosis. A colonogenic assay shows that only the
p53 mutation influenced the ability of CV1 cells to form colonies whilst all
other tumourigenic mutations did not show a significant difference in the
colony formation ability of the cells compared to WT CV1. Figure 4.4F.
104
105
Figure 4.4: Analysis of cell proliferation in WT and transformed
CV1 cells by MTT assay, PI staining and clonogenic assay. (A)
Cell proliferation evaluated at different time points by the MTT assay.
Results represent the means ± standard deviation of two experiments per-
formed in triplicate (n=6). (B) Proliferation Index, the average number of
divisions of just the responding cells (cells that underwent at least one di-
vision), was calculated using data generated by flow cytometry from lysed
and PI stained cells through FlowJo 7.6.4. proliferation platform. Same
number of cells was seeded in 24 well plates and cultured for 72 hours
before analysis. (C) Percent divided is the calculated percentage of cells
that divided at least once calculated by an integrated algorithm in FlowJo
7.6.4. D and E: Cell cycle distribution of WT and transformed
CV1 cells. (D) Histograms of DNA content in WT CV1 and transformed
CV1 cells generated by FlowJo 7.25 analysis of lysed and PI stained cells
that were seeded at the equal densities in 24 well plates and cultured in
complete medium for 72hrs. (E) The percentage of cells in subG1, G1, S
and G2/M phase of the cell cycle analysed using the cell cycle platform of
FlowJo 7.6.4 software. Results are representative of at least two indepen-
dent experiments. Data shown are the means ± standard deviation. *p
value<0.05 and **p value<0.01. (F) Colony forming ability of single cells
was assessed by the plate clonogenic assay that was performed as described
in materials and methods. The quantitative data are shown as the mean of
triplicates ± standard deviation of one experiment (n=3). For all assays,
paired, one-tailed Student’s t-test was used to determine the significance
of the differences between different cells. *p value<0.05.
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4.3 Other anticancer genes exert different effects on
oncogene-transformed CV1 cells
The effects of established anticancer genes other than ORCTL3, such as
Mda-7/IL24, Par-4 and Apoptin were also investigated on WT and trans-
formed CV1 cells. In agreement with their known tumour specific effect
and similar to ORCTL3, all genes did not induce apoptosis in parental
CV1 cells. On the other hand, all tumourigenic mutations activated Par-
4 for apoptosis induction. At the same time, Apoptin was activated in
all transformed cells with the exception of p53-mut transformed cells, and
Mda-7/IL24 was activated by all tumourigenic mutations except E6 and
Myc mutations. Interestingly and just like ORCTL3, all three anticancer
genes remained ineffective in E1A transformed cells. Figure 4.5A.
The response of all the cells to recombinant TRAIL protein was also inves-
tigated. Figure 4.5B shows a high activation of TRAIL-induced apoptosis
in all transformed cells whilst WT CV1 and E1A CV1 cells remained un-
affected.
Mda7/IL24, Par-4 and Apoptin, in addition to ORCTL3, were also tested
on HeLa cells to confirm their ability to induce apoptosis in cancer cells
and Figure 4.6 shows the different activities of these proteins in those
cells compared to ORCTL3 and the positive control caspase-2.
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Figure 4.5: Other anticancer genes remain ineffective in parental
CV1 cells whilst most of them become active for apoptosis induc-
tion in transformed CV1. (A) WT and transformed CV1 cells were
co-transfected with GFP-expressing plasmid and plasmids expressing other
established anticancer genes: IL24, Par-4, and Apoptin at a 1:3.3 ratio us-
ing Xfect transfection reagent. Percentage of apoptosis was calculated by
counting GFP-positive cells that showed apoptotic morphology compared
to all GFP-positive cells. Light microscopy pictures were taken to cover the
entire well area and at least 500 cells were counted per well. Values repre-
sent the mean of three different experiments ± SD (n=3). *p value<0.05
and **p value<0.01.
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Figure 4.5: contd. (B) TRAIL shows a specific apoptosis induction effect
in all transformed CV1 and no effect in WT CV1 or CV1 overexpressing
E1A. WT and transformed CV1 cells were seeded in 24-well plate and kept
overnight. Cells were treated with 10ng/ml of the recombinant humanised
TRAIL (Invitrogen). 24 hours after treatment, cells were harvested and
stained with fluorescein diacetate that stains only viable cells leaving dead
cells unstained. Percentage of dead (unstained) cells that showed no fluo-
rescent signals was quantified by flow cytometry (channel FL1) compared to
viable (stained) cells. Data were analysed by FlowJo 7.6.4. Data represent
means±SD of three independent experiments (n=3). ***p value<0.001.
Figure 4.6: The effect of other anticancer genes on HeLa cell line.
HeLa cells were transfected with ORCTL3 and other known anticancer
genes: IL24, Par-4 and Apoptin in addition to β-Gal and Caspase2, as
negative and positive controls, respectively. Apoptosis was assessed 24
hours post transfection using DiOC6 /PI staining and subsequent analysis
by flow cytometry. Data are means of three independent experiments ±
SD (n=3). Raw data were normalised to transfection efficiency estimated
by GFP. **p value<0.01 and ***p value<0.001.
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4.4 ORCTL3 causes activation of the ARCosome
The physical proximity of components of the ARCosome and ORCTL3
at the ER and the involvement of both in apoptosis signalling advocated
the idea of a possible functional interaction between ORCTL3 and com-
ponents of the ARCosome. This speculation was tested using a premade
fusion protein of Bap31-EYFP that was described by Iwasawa et al.[84].
This fusion protein allows monitoring the processing and the cleavage of
Bap31 upon the introduction of a new apoptosis signal[84]. Figure 4.7A.
A co-transfection of this construct with ORCTL3 resulted in the cleavage
of 50% of Bap31-EYFP 18 hours post-transfection. Figures 4.7B,C. Cell
death assessment of these cells showed no detectable apoptosis induction
at this time point, Figures 4.7D,E, suggesting that ORCTL3 overexpres-
sion leads to the cleavage of Bap31 as an early event of its apoptosis sig-
nalling. Moreover, when the three components of the ARCosome, Bap31,
Fis1 and caspase-8, were individually downregulated (knockdown cells were
generated by Iwasawa et al.), a significant reduction in apoptosis induced
by ORCTL3 was observed in each knockdown cell population. Figures
4.8A,B,C.
4.5 ORCTL3 causes an incomplete ER stress response
Irshad et al. showed previously that not only ORCTL3 accumulates in
the ER, but also that ORCTL3 overexpression induces an unusual ER
stress response that results an upregulation of ATF4 but not BiP/Grp78
in tumour cells. These findings were very unexpected and could be con-
firmed in this study when ATF4 and BiP protein levels were measured with
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Figure 4.7: ORCTL3 overexpression results in Bap31-EYFP cleav-
age as an early event of its apoptosis signalling. (A) As described by
Iwasawa et al.: Bap31 was C-terminally tagged with EYFP. Bap31 has two
caspase cleavage sites (D164 and D238, shown as triangles) and three frag-
ments are produced upon cleavage. One of them is EYFP with an eight
amino acid extension. (B) Bap31-EYFP was co-transfected with β-Gal
or ORCTL3 (120ng+480ng, respectively) into HeLa cells seeded in 6-well
plate. Cells were harvested and lysed at the indicated time points post-
transfection, separated by SDS-PAGE and immunoblotted with anti-GFP
antibody to detect the cleavage of Bap31. β- Actin was used as a loading
control. (C) The cleavage of Bap31 was quantified using ImageJ software
that determines the intensity of the bands on a given western blot film.
The ratio between the intensities of the cleaved Bap31-EYFP and the full
length Bap31-EYFP was calculated and blotted in this histogram. Each
bar represents the mean of two independent experiments ± SD (n=2). (D)
HeLa cells were co-transfected with Bap31 and either β-Gal or ORCTL3 in
a 1:4 ratio. 24 hours post-transfection apoptosis was quantified by staining
the cells with DiOC6/PI and analysing the staining pattern of the cells
using FL1 and FL3 channels of flow cytometry. Bars represent the average
of three individual experiments± standard deviation, n=3. Raw data were
normalised to transfection efficiency estimated by GFP. **p value<0.01 and
***p value<0.001. (E) Light microscopy pictures of ORCTL3 transfected
cells 18 hours post-transfection (when Bap31-EYFP cleavage has already
started). When compared to β-Gal transfected cells at the same time point,
no morphological differences were observed between the two plasmids in-
dicating a very early stage of apoptosis that is induced eventually at later
time points by ORCTL3.
112
Figure 4.8: Knockdown of the ARCosome components reduce
apoptosis induced by ORCTL3. HeLa cells were downregulated for
the individual components of the ARCosome: (A) Fis1, Bap31 or (B)
Caspase8 (Iwasawa et al.). Knockdown and scramble cells were transfected
simultaneously with ORCTL3 expressing plasmid and β-Gal as a negative
control. Apoptosis was measured by quantifying the mitochondrial mem-
brane potential (DiOC6 staining) and the plasma membrane integrity (PI
staining) using flow cytometry (FL1 and FL3) 24 hours after transfection.
Raw data were normalised to transfection efficiency estimated by GFP for
each cell type. Data represents the mean ± SD of three separate experi-
ments (n=6). *p value<0.05, **p value<0.01, and ***p value<0.001. (C)
Western blotting against Bap31, Fis1, and caspase-8 to show the downreg-
ulation compared to scramble cells.
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western blotting upon ORCTL3 overexpression. Figure 4.9A. To study
this effect even further, the upregulation of other ER UPR sensors was
also investigated. Figure 4.9A shows no upregulation of the proapoptotic
transcription factor CHOP. In addition, blotting for TRAF2 showed no
differences in TRAF2 expression level between ORCTL3 and β-Gal trans-
fected cells. Nevertheless, ORCTL3 overexpression induced the splicing of
XBP-1 mRNA, a signal that is more upstream in the ER UPR compared
to ATF4 or CHOP. Figure 4.9B. When ATF4 was down-regulated in the
cells, the apoptosis induced by ORCTL3 was weakly but significantly re-
duced. Figure 4.10A. The knockdown of BiP, on the other hand, did not
increase apoptosis induced by ORCTL3 as expected, instead the apoptosis
induced was slightly decreased. Figure 4.10B.
ER stress is also known to be induced by inhibiting N-glycosylation of pro-
teins, a mechanism by which tunicamycin induces ER stress[239]. Because
ORCTL3 is a heavily glycosylated protein, with four N-glycosylation sites,
the glycosylation status of proteins in the cells upon ORCTL3 expression
was examined, as the overexpression of a heavily glycosylated protein might
result in the inhibition of glycosylation of other glycosylated proteins. This
was indirectly achieved by looking at the glycosylation status of COX-2
protein. COX-2 is an enzyme that is involved in the ER stress response in
addition to other cellular pathways[240]. It also has four glycosylation sites
and inhibition of N-glycosylation, by treatment with tunicamycin for ex-
ample, results in the expression of COX-2 with a reduced molecular mass,
which can be detected on western blot[240, 241]. Figure 4.9A shows that
while tunicamycin treatment resulted in the detection of COX-2 with re-
114
duced molecular mass in addition to the full length protein, ORCTL3 did
not affect the glycosylation status of COX-2 under these conditions.
These results show that ORCTL3 expression results in a partial activation
of the conventional ER stress response and consequently the involvement
of some but not all key players of ER stress.
4.6 ORCTL3 interacts with stearoyl-CoA desaturase
for tumour-specific apoptosis induction
Morgan-Lappe et al. showed in an RNAi screen that stearoyl-CoA desaturase-
1 downregulation causes apoptosis in tumour cells but not in normal cells[210].
Minville-Walz et al. showed that the apoptosis induced by downregulated
SCD-1 in cancer cells is mediated by an ER stress response that is, inter-
estingly, similar to the one triggered by ORCTL3 and leads to splicing of
XBP-1 and no BiP upregulation[222]. Moreover, Masuda et al. showed an
upregulation of ATF4 and also splicing of XBP-1 upon chemical inhibition
of SCD-1[224]. Because of the similarity of the ER stress responses induced
by ORCTL3 and SCD-1, and since both proteins reside in the ER, an in-
teraction between the two proteins was hypothesised and I asked whether
ORCTL3 targets SCD-1 to induce apoptosis.
Figure 4.11A reveals that H-Ras- and p53- transformed CV1 cells har-
bour an upregulated SCD-1 compared to WT CV1. Interestingly, the in-
hibition of SCD-1 caused by the application of a specific chemical com-
pound, CAY10566, resulted in higher apoptosis induction in H-Ras- and
p53-transfomred cells than in their normal counterparts. Figure 4.11B.
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Figure 4.9: ORCTL3 triggers an incomplete ER stress response.
(A) HeLa cells were transfected with plasmids expressing either ORTCL3
or β-galactosidase as a negative control. As positive control for ER stress,
cells were treated with 5ng/µl tunicamycin for eight hours. At each spec-
ified time point post transfection, cells were harvested and proteins were
lysed. Equal amounts of proteins were separated on SDS-PAGE gels and
immunoblotted for different ER stress markers: chaperone protein BiP,
ATF4, CHOP, TRAF2 and COX2. β-actin and GAPDH were also blotted
as negative controls. (B) HeLa cells were transfected with either ORCTL3
or β-galactosidase as a negative control. Cells were harvested 24 and 48
hours post-transfection and total RNA was isolated. RNAs underwent re-
verse transcription for cDNA production and cDNAs were then used as
templates for two PCRs; one with a primer set specific to XBP-1 and a
second PCR to amplify β-actin as a control. PCR products were separated
on a 3.5% agarose gel.
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Figure 4.10: ATF4 and BiP downregulation reduce apoptosis in-
duction by ORCTL3. ATF4 and BiP were downregulated in HeLa cells
using specific shRNA plasmid and stable clones were generated. Cells trans-
fected with scramble plasmid were used as a negative control. Downregu-
lation of ATF4 and BiP was confirmed by immunoblotting the cell lysates
of the knockdown cells compared to scramble cells for ATF4 and BiP using
specific antibodies. (A) Both ATF4 knockdown cells and scramble cells
were transfected with β-galactosidase as a negative control, Bax as a speci-
ficity control, and ORCTL3. (B) Both BiP knockdown cells and scramble
cells were transfected with β-galactosidase as a negative control, Bax and
caspase-8 as specificity controls, and ORCTL3. (A) and (B) 24 hours post
transfection, apoptosis was evaluated by DiOC6/PI staining and flow cy-
tometry analysis. Data represent means of three independent experiments
± SD. Raw data were normalised to transfection efficiency estimated by
GFP. * for ATF4 = p value of 0.0142. * for BiP =p value of 0.014364.
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To show the involvement of SCD-1 in ORCTL3 induced apoptosis, H-Ras-
and p53- transformed CV1 cells were transfected with either ORCTL3 or
capsape2 as a control. BSA-complexed oleic acid, the product of SCD-1,
and BSA only were added to the transfected cells. Figure 4.12A shows
that the apoptosis induced by ORCTL3 only and not by caspase-2 was sig-
nificantly reduced when transfected cells were exogenously supplemented
with oleic acid. Furthermore, a physical interaction between ORCTL3
and SCD-1 was evidenced in a co-immunoprecipitation performed in 293T
and HeLa cells presented in Figures 4.12B and C. In addition, a co-
transfection of ORCTL3 and SCD-1 in a 1:3 ratio into 293T cells specifi-
cally reduced apoptosis induced by ORCTL3 and not by other apoptosis
inducers, such as RIP or ANT1. Figures 4.12D,E. These results suggest
that SCD-1 activity is required for the survival of transformed cells but not
WT CV1 cells, and that at least one of the apoptosis signals induced by
ORCTL3 in the transformed cells targets SCD-1 activity in these cells.
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Figure 4.11: SCD-1 is upregulated in transformed CV1 compared
to WT CV1 and transformed CV1 cells are more sensitive to
apoptosis induced by SCD-1 inhibition. (A) Endogenous SCD-1
mRNA level was semi-quantified by RT-PCR in WT CV1, H-Ras trans-
formed CV1 and p53-Mut CV1. An aliquot of these three cells was pro-
cessed for total RNA isolation, cDNA generation, and PCR amplification
using a set of primers specific for SCD-1 and β-actin as loading control.
PCR products were separated on 1.5% agarose gel. (B) WT CV1, H-
Ras and p53-mut transformed CV1 were treated with different concentra-
tions of the specific SCD inhibitor CAY10566 and similar volumes of its
solvent DMSO as a negative control. 48 hours post-treatment apoptosis
was evaluated by fluorescein diacetate staining that stains only viable cells
leaving dead cells unstained. Percentage of dead (unstained) cells that
showed no fluorescent signal was quantified by flow cytometry (channel
FL1) compared to viable (stained) cells. Data were analysed by FlowJo
7.6.4. Background apoptosis level generated by DMSO addition only was
subtracted from reach relevant reading. Data represent means ± SD of
three independent experiments (n=3). *p value<0.05, **p value<0.01 and
***p value<0.001. Asterisks indicate values that are significantly different
from apoptosis induction by the same concentration in WT CV1.
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Figure 4.12: ORCTL3 targets stearoyl-CoA for tumour-specific
apoptosis induction. (A) CV1 cells transformed by overexpression of
H-Ras and mutant p53 were transiently co-transfected with a plasmid ex-
pressing GFP and either luciferase, ORCTL3 or Caspase2 in a 1:3.3 ratio.
5 hours post-transfection cells were treated with 100µM of either BSA-
conjugated oleic acid or BSA only as a negative control for 24 hours.
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Figure 4.12: contd. Apoptosis was evaluated by counting transfected cells
that were undergoing apoptosis compared to all transfected cells. At least
500 cells were counted. Data represent means ± SD of duplicates ob-
tained from two independent experiments, (n=4). **p value<0.01 and ***p
value<0.001. Values marked with asterisks are significantly different from
the BSA control. (B) An interaction between ORCTL3 and SCD-1 shown
by immunoprecipitation. ORCTL3-HA was transfected in 293T cells. 24
hours after transfection, cells were lysed using Tris/Triton buffer and im-
munoprecipitated with either an antibody against HA (right panel) or an
antibody against endogenous SCD-1 (middle panel). The immunoprecipi-
tates were probed on western blot for endogenous SCD-1 or ORCTL3-HA,
respectively. (C) ORCTL3-HA was co-transfected with SCD-1 in HeLa
cells in a 1:1 ratio (right, input). Cell lysates were prepared using Pierce
IP lysis buffer and immunoprecipitated with α-HA antibody (Left). The
immunoprecipitate was analysed by western blot for SCD-1 using α-SCD-1
antibody. (D) 293T cells were transfected with ORCTL3, RIP and ANT1
with either β-Gal or a plasmid expressing SCD-1 in 1:3 ratio using JetPEI
transfection reagent. 48 hours post-transfection, apoptosis was assessed by
staining the cells with DiOC6/PI and analysing the staining pattern of the
cells using flow cytometry and FlowJo 7.6.4. Data represent the means of
triplicates of one representative experiment ± SD, (n=3). Raw data were
normalised to transfection efficiency estimated by GFP. **p value<0.01.
(E) Representative pictures of the cells that were processed in D before
harvesting for apoptosis staining.
4.7 Mouse ORCTL3 but not its human homologue
can induce apoptosis in transformed cells
The mouse ORCTL3 and its human homologue are 84% similar and 73%
identical at the protein level. Although it was anticipated that both pro-
teins might be similar in their apoptosis induction activity when overex-
pressed in tumour cells, the results obtained for the human ORCTL3 were
surprising. When human ORCTL3 was transfected in the transformed
HeLa and 293T cell lines, no noticeable apoptosis was detected in either
cell line. Figure 4.13A. When the expression levels of human and mouse
ORCTL3 proteins were determined, results showed a significantly higher
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stability of the mouse protein in the cells. Figures 4.13B,C. Moreover,
even when more plasmid expressing the human gene was transfected into
the cells in a titration experiment, apoptosis induced by this gene remained
considerably lower than the cell death induced by mouse ORCTL3. Figure
4.13D
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Figure 4.13: Apoptosis induction activity is an exclusive feature for
mouse ORCTL3 and not human ORCTL3. (A) HeLa and 293T cells
were transfected with Luciferase, as a negative control, a plasmid expressing
mouse ORCTL3 and a plasmid expressing human ORCTL3. 24 hours
post-transfection, apoptosis in both cell lines was evaluated by DiOC6/PI
staining followed by flow cytometry analysis. Bars represent the percentage
of cells that are DiOC6-negative and PI -negative or -positive compared to
all cells. The means ± SD of three independent experiments was shown,
(n=3). Raw data were normalised to transfection efficiency estimated by
GFP. **p value<0.01 and ***p value<0.001. (B) The levels of mouse
and human ORCTL3 protein transfected into HeLa and 293T cells were
compared by immunostaining the transfected cells with Alexa488-labelled
antibody against HA, that was fused to both mouse and human ORCTL3,
and measure the mean intensity of all positive cells and the percentage of
positive cells compared to all cells. Bars represent the means ± SD of three
independent experiments, n=3. *p value<0.05 and **p value<0.01.
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Figure 4.13: contd. (C) The histograms below were blotted by FlowJo
7.6.4 and show the peaks for the signals at the correct channel and the
shift to the right for the positive signals. Cells transfected with Luciferase
acted as negative control. (D) HeLa cells were transfected using Effectene
with varying concentrations of the mouse and the human ORCTL3 plas-
mids. The DNA:effectene reagent ratio was always maintained at the rec-
ommended value. Different concentration of β-Gal was used as a neg-
ative control for each concentration and the background noise was sub-
tracted from each reading. The upper panel shows apoptosis levels as-
sessed by DiOC6/PI staining and the lower panel shows the corresponding
expression levels of the plasmids using immunostaining with a labelled an-
tibody against HA. Both analyses were performed using flow cytometry
and FlowJo 7.6.4 software. All analyses were performed 24 hours after
transfection in 24 well format.
4.8 Transmembrane domains 3 and 4 of the mouse
ORCTL3 gene are mainly responsible for its apop-
tosis induction activity
It was still unknown at that stage whether the exclusivity of the apoptosis
induction effect to the mouse ORCTL3 was due to the mere accumulation
of the protein in the cells or whether the mouse ORCTL3 contains unique
pro-apoptotic sequences. This is the reason why it was important to map
the domain(s) responsible for this exclusive apoptosis effect.
Irshad et al. described a deletion construct of mouse ORCTL3 that com-
prises the first 5 transmembrane (TM) domains of the protein and still
induced apoptosis[212]. Since this was the smallest deletion construct that
was tested, it was the starting point for further progressive deletions that
were generated from this construct (TM5). At first, four deletion constructs
were generated: one with three TMs (TM3), one with two TMs (TM2) and
two constructs with only one TM but with different lengths (TM1a and
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TM1b). Figure 4.14A. None of the newly generated constructs induced
apoptosis when overexpressed in the cells. Figure 4.14B. The expres-
sion levels of the proteins encoded by these constructs were measured by
immunostaining that was analysed by FACS, a more precise approach to
monitor the various expression levels in the sub-populations, and western
blotting. Results obtained from both techniques showed that in addition to
WT ORCTL3 and TM5, only TM2 was expressed to an appreciable level
but neither TM1a nor TM1b were stable. Figures 4.14C,D. TM3 showed
a weak expression on the western blot but no stable protein with FACS im-
munostaining. Since TM5 induced apoptosis, TM2 was expressed but did
not induce apoptosis, and TM3 was not stable, further fine-mapping of
TM4 and 5 was carried out.
The second round of deletion construction involved the generation of four
new constructs: TM5a, contains the first 5 TM domains with no additional
amino acids at the C-terminus, TM5b, where half of TM5 was deleted,
TM5c, where TM5 was deleted but the loop between TM4 and TM5 was
retained, and finally TM4, a construct that harbours the first four TM
domains. Figure 4.15A. Apoptosis assay for the overexpression of these
constructs revealed that amongst these four constructs only TM4 retained
an activity for apoptosis which was even more efficient than apoptosis in-
duced by the larger construct TM5. Figure 4.15B. This correlated pre-
cisely with the expression levels of all constructs. Figures 4.15C,D. Given
that the first four TM domains are sufficient for efficient apoptosis induc-
tion, the deletion of the fourth TM domain resulted in an unstable protein
that does not exert any apoptosis activity, and TM2 was stably expressed
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Figure 4.14: First round of mapping ORCTL3. (A) A schematic illus-
tration of the constructed C-terminal deletions of the WT mouse ORCTL3.
Blue coloured segments represent the transmembrane domains of the pro-
tein. (B) All deletion constructs, WT ORCTL3, and Luciferase plasmids
were transfected into HeLa cells and cells were scored for apoptosis us-
ing DiOC6/PI staining. Data are the means ± SD of three independent
experiments,(n=3). Raw data were normalised to transfection efficiency
estimated by GFP. *p value< 0.05, **p value<0.01.
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Figure 4.14: cont. (C) Since all the deletion constructs were tagged with
HA, the expression level of each construct was quantified using immunos-
taining with a labelled antibody against HA and acquisition with FL1 chan-
nel of flow cytometry. (D) The expression levels of the deletion constructs
by western blotting. Total protein lysates of HeLa cells that were trans-
fected with the deletion constructs generated in (A) were separated on
SDS-PAGE gels and immunoblotted with an antibody against HA tag that
was fused to all constructs. Maximum amount of protein was loaded in all
cases to detect even minimal expression levels.
but did not induce apoptosis, the focus was turned to design a construct
harbouring TM3 and 4 and test its sufficiency to induce cell death.
The third round of deletions construction involved the generation of three
different constructs that encompass TM domains 3 and 4 only but with mi-
nor changes: NTM34 contains TM3 and 4 that are fused to the N-terminal
signal sequence of ORCTL3. NPosTM34 contains the sequence of NTM34
with an additional two positively charged arginine residues between the N-
terminus and TM3. Finally, TM34 contains TM3 and 4 only with the loop
in between them. Figure 4.16A. None of these constructs could initiate
cell death. Figure 4.16B. In addition, none of these constructs were found
to be stable in the cells. Figures 4.16C,D. The band seen in the first lane
of the western blot in figure 4.16D is an artefact as the expected size of
the NTM34 construct is 7.8 KDa whereas this non-specific band appears
at around 12KDa.
Even though it was not possible to stabilise these two TM domains in the
experimental settings above, it was nevertheless speculated that these two
mouse TM domains, if put into the correct context for sufficient expression,
could be the functional domains of the mouse ORCTL3 for its apoptosis in-
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Figure 4.15: Second round of mapping ORCTL3. (A) A schematic
sketch of further fine-mapping deletions of transmembrane 5 were generated
with the smallest construct containing the first four transmembranes only.
All constructs were C-terminally tagged with HA.
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Figure 4.15: cont. (B) Plasmids containing all constructs from A in ad-
dition to WT ORCTL3, TM5 (for comparison), and Luciferase (as a neg-
ative control) were transfected into HeLa cells. 24 hours post-transfection,
apoptosis was quantified by DiOC6/PI staining and flow cytometry anal-
ysis. Data are means ± SD of three independent experiments,(n=3).
Raw data were normalised to transfection efficiency estimated by GFP. *p
value<0.05, **p value<0.01, and ***p value<0.001. (C) Immunostaining
of HeLa cells transfected with the deletion constructs above was performed
using Alexa 488 labelled-antibody against HA. Signals were acquisitioned
using channel FL1 in flow cytometry and analysed using FlowJo 7.6.4. Sig-
nals were compared to background noise generated by the negative control,
luciferase. (D) The expression levels of the deletion constructs by western
blotting. Total protein lysates of HeLa cells that were transfected with the
deletion constructs generated in (A) were separated on SDS-PAGE gels
and immunoblotted with an antibody against HA tag that was fused to all
constructs. Maximum amount of protein was loaded in all cases to detect
minimal expression.
duction. I took advantage of the lack of apoptosis induction activity in the
human gene and inserted TM3 and 4 from the mouse gene into the exact
site of the human TM3 and 4 to generate DSTM3&4. Figure 4.17A. The
question I was trying to address was: if the full length human gene context
that does not induce apoptosis could stabilise mouse TM domains 3 and
4, could mouse TM3 and 4 enable human ORCTL3 to induce apoptosis?
The answer to this question was revealed in Figure 4.17B which shows
that DSTM3&4 caused apoptosis as efficiently as the mouse ORCTL3. The
expression of this construct was significantly higher than the human OR-
CTL3. Figure 4.17C. Do the mouse TM domains 3 and 4 stabilise the
human ORCTL3 to enable it to induce apoptosis? Or do they comprise
specific sequences that trigger an apoptosis signal?
To resolve this puzzle, I opted to look into the area of TM3 and 4 in more
details. Mouse and human TM domains 3 and 4 differ in a number of amino
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Figure 4.16: Third round of mapping ORCTL3. (A) Three small
constructs containing transmembrane domain 3 and 4 were generated.
Subtle changes in the three constructs were made: NTM34 contains the
N-terminus of the protein, NPosTM34 contains, towards the end of the
N-terminus, two arginine residues, and TM34 contains only the two trans-
membrane domains.
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Figure 4.16: contd. (B) All three constructs, luciferase, and WT ORCTL3
were transfected into HeLa cells and apoptosis was quantified 24 hours after
transfection using DiOC6/PI staining and flow cytometry. Data are means
± SD of three independent experiments,(n=3). Raw data were normalised
to transfection efficiency estimated by GFP. ***p value<0.001. (C) Ex-
pression levels of the three constructs were assessed using immunostaining
with a labelled antibody against HA tag that is fused to all constructs. Sig-
nals were quantified using FL1 channel in flow cytometry compared to the
signals obtained from the negative control, luciferase. (D) The expression
levels of the deletion constructs by western blotting. Total protein lysates
of HeLa cells that were transfected with the deletion constructs generated
in (A) were separated on 18% SDS-PAGE gels and immunoblotted with
an antibody against HA tag that was fused to all constructs. Maximum
amount of protein was loaded in all cases to detect even minimal expression
levels.
acids and the loop flanked by the two domains contains only one amino acid
exchange between the two homologues. Using recombinant PCR, the TM
domains were swapped individually from the mouse to the human gene and
a single point mutation was introduced to the loop domain of the human
gene to resemble the mouse gene’s loop. Figure 4.18A. None of these
constructs was able to induce apoptosis and at the same time none of them
was expressed to a significant level. Figures 4.18B,C. This indicates that
mouse TM3 and 4 are both vital for the accumulation of the protein and
that the accumulation of the protein is important for apoptosis induction.
The logical next question was whether swapping the mouse TM domains
3 and 4 with the human domains would abolish the apoptosis induction
activity and/or the stability of the protein produced by the mouse gene.
DSTM3&4HtoM was the construct produced by inserting the two human
TM domains into the mouse ORCTL3 gene. Figure 4.18A. Figure 4.18B
shows a very weak apoptosis caused by this construct despite its high ex-
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Figure 4.17: Domain Swappings between mouse and human OR-
CTL3 genes reveal the importance of transmembrane 3 and 4
from the mouse gene for apoptosis induction. (A) A schematic
representation of swapping transmembrane 3 and 4 from the mouse gene
into the human full length gene to generate (DSTM3&4). Construct was
confirmed by sequencing.
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Figure 4.17: contd. (B) Apoptosis quantification in HeLa cells 24 hours
after transfecting the human ORCTL3 containing the mouse TM3 and 4
(DSTM3&4) shows an apoptosis induction effect of the construct when
compared to WT human ORCTL3. Data are means ± SD of three in-
dependent experiments,(n=3). Raw data were normalised to transfection
efficiency estimated by GFP. ***p value<0.001. (C) Histograms showing
the expression level variations of mouse ORCTL3, human ORCTL3 and
DSTM3&4. Expression was measured by immunostaining with a labelled
antibody against HA.
pression level which is comparable to the WT mouse protein. Figure
4.18C. This suggests the presence of unique sequences within the mouse’s
TM domains 3 and 4 that are likely to be responsible for exerting the signal
that induces apoptosis.
Finally, since the smallest construct of the mouse ORCTL3 that was capa-
ble of inducing apoptosis was identified. This construct, TM4, was fused
to the ER retention signal, which was used by Irshad et al. to retain WT
ORCTL3 in the ER, in order to make this construct even more efficient
for apoptosis induction. As expected, Figure 4.19 shows more efficient
apoptosis induced by this fusion protein when compared to TM4 only.
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Figure 4.18: Domain swappings between mouse and human OR-
CTL3 genes reveal the importance of transmembrane 3 and 4
from the mouse gene for apoptosis induction. (A) A diagram shows
swapping of smaller domains from mouse gene to human: TM3 only, TM4
only, and a point mutation (A to T) in the extracellular loop between
TM3 and TM4 in the human gene. An additional construct was also
generated by swapping the mouse TM3 and TM4 area with the human
domains (DST3&4HtoM). All constructs were confirmed by sequencing.
(B) Constructs from A were transfected into HeLa cells along with WT
mouse and WT human genes. Apoptosis was quantified 24 hours post-
transfection using DiOC6/PI staining and subsequent flow cytometry anal-
ysis. Transfection background level generated by transfecting luciferase was
subtracted from all readings. Data are means ± SD of three independent
experiments,(n=3). Raw data were normalised to transfection efficiency
estimated by GFP. *p value<0.05.
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Figure 4.18: contd. (C) Using a labelled antibody against HA, transfected
cells were immunostained and analysed by flow cytometry to quantify the
protein expression level encoded by each construct. Bars represent the
mean intensity of the signal acquired by channel FL1 in the flow cytometry
compared to the signal generated by the negative control. Above each
column is the percentage of positively stained cells.
Figure 4.19: TM4 targeted to the ER induces more efficient apop-
tosis that TM4 only. The deletion construct that consists of the first
four transmembrane domains was fused to an ER retention signal at the
C-terminus to generate TM4ER. This construct along with TM4 and Lu-
ciferase were transfected into HeLa cells and 24 hours post-transfection
apoptosis was evaluated by DiOC6/PI staining. Data are the means of
three independent experiments ± SD, n=3. Raw data were normalised to
transfection efficiency estimated by GFP. **p value<0.01.
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4.9 Mouse ORCTL3 and not its human homologue
can also induce apoptosis in transformed mouse
cells
The effect of the mouse ORCTL3 in the human cells was not a consequence
of an incompatibility of the mouse protein in the human cellular environ-
ment. This was concluded from testing the effect of the mouse ORCTL3
gene in mouse cells. N2A cells underwent apoptosis upon the overexpres-
sion of mouse ORCTL3 but not the human gene. Figure 4.20A. Accu-
mulation of mouse ORCTL3 was also higher in these cells than the human
equivalent. Figures 4.20B,C.
4.10 An adenovirus expressing ORCTL3 causes sub-
stantial and specific apoptosis in oncogene- trans-
formed CV1 cells
The observation that TRAIL treatment of the transformed CV1 cells (above)
resulted in more pronounced effect than transfecting the cells with the dif-
ferent anticancer genes and the conclusion made from the mapping exper-
iments about the importance of sufficient accumulation of ORCTL3 for its
apoptosis induction inspired me to use an adenovirus vector that expresses
ORCTL3 as vehicle to efficiently transport the gene into the cells and ex-
press it to a very high level. Moreover, retaining either the mouse WT
ORCTL3[212] or TM4 construct to the ER brought about more efficient
apoptosis inductions. Considering all above evidence, an adenovirus vector
expressing mouse ORCTL3 with an ER retention signal was produced. In
addition, two more viral vectors expressing GFP and Luciferase were pro-
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Figure 4.20: Mouse only and not human ORCTL3 induces apopto-
sis in transformed mouse cells. Similar to human cancer cells, mouse
cancer cells undergo apoptosis by overexpressed mouse ORCTL3 only and
not human ORCTL3. (A) N2A cells were transfected with mouse ORCTL3
gene (mORCTL3), human ORCTL3 gene (hORCTL3), β-Gal as a nega-
tive control and caspase-2 as a positive control. Apoptosis was evaluated
by double staining with DiOC6/PI and flow cytometry analysis using chan-
nel FL1 and FL3. Data are the means of three independent experiments±
SD, n=3. Raw data were normalised to transfection efficiency estimated by
GFP. *p value<0.05, **p value<0.01 and ***p value<0.001. (B) Mouse
and human ORCTL3 were both tagged with HA tag. Expression levels of
both proteins were quantified by immunostaining with an Alexa-488 conju-
gated antibody against HA. Signal was quantified using FL1 channel in flow
cytometry and the bars represent the mean signal intensity at this channel.
The percentage of stained cells is shown above the bars. p value=0.000353.
(C) The histogram on the right is the data output of the signals at channel
FL1.
138
duced at the same titer. GFP expressing adenovirus was used to transfect
WT CV1 and the tumourigenic transformed variants in order to estab-
lish the infection conditions at which equal expression levels of the virus
is achieved in all cells. The same viral titers were then used in the subse-
quent experiments. Adenovirus vectors expressing ORCTL3 and luciferase
as a negative control were used to infect WT and transformed CV1 cells.
Figure 4.21A shows that the expression of ORCTL3 by this vehicle did
not cause any cell death in the non-transformed cells while all other trans-
formed cells, including E1A transformed CV1 cells that previously had not
responded to transfection of the ORCTL3 expression plasmid, showed sig-
nificant level of cell death 24-hours post-infection. Figure 4.21A. Figure
4.21B shows the differences of the expression levels of ORCTL3 delivered
by the virus to the cells.
When the apoptosis induced by the ORCTL3-expressing adenovirus in nor-
mal and transformed CV1 cells (shown in Figure 4.21A) was normalised
to the differences in the expression levels of ORCTL3 in these cells as de-
tected by immunostaining (shown in Figure 4.21B), the resulting figures
show that if 100% infection efficiency and therefore expression of ORCTL3
in 100% of the cells can be reached, ORCTL3 would induce cell death in
almost 100% of Myc-transformed cells, in a round 70% of E6-transformed
cells, 50% of H-Ras and p53 transformed cells, 20% of E1A-expressing cells
and none of the WT CV1 cells. Figure 4.21C.
139
Figure 4.21: An adenovirus expressing ORCTL3 causes substantial
apoptosis only in oncogene-transformed cells and not in normal
cells. (A) WT CV1 and oncogene-transformed CV1 cells were infected
with an ORCTL3ER-expressing adenovirus at a multiplicity of infection
(MOI) to reach approximately equal expression level in all cells.
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Figure 4.21: contd. GFP- and Luciferase-expressing adenoviruses were
also used to infect the cells as infection and negative controls, respectively.
24 hours post-infection, apoptosis induced by ORCTL3 was quantified by
staining viable cells with fluorescein diacetate and comparing the percent-
age of unstained cells to total cell number between different cell types.
Toxicity induced by the viral infection itself was subtracted by subtracting
the signal caused by the Luciferase-expressing virus. Data are means ± SD
of three independent experiments, (n=3). *p value<0.05, **p value<0.01,
***p value<0.001. (B) Infected cells were immunostained with a labelled
antibody against HA and analysed by flow cytometry. Bars represent the
means ± SDs of the percentages of HA-positive cells from two indepen-
dent experiments where each sample was processed in duplicate, (n=4). *p
value<0.05 compared to WT CV1. (C) Normalisation of the cell death
induced by ORCTL3-expressing adenovirus shown in A to the expression
levels of ORCTL3 determined by immunostaining against HA shown in B.
4.11 The effect of ORCTL3-adenovirus on primary
normal and tumour cells
Experiments were performed on minimally passaged primary normal and
tumour renal cells obtained from the same patient each. A total of six tissue
specimens (3 from normal cortex plus 3 from clear cell renal cell carcinoma
(RCC)) were maintained in culture and examined. Similar to what has
been reported in the study performed by M. J. Valente et al., normal kid-
ney epithelial cells showed higher proliferation rates than tumour cells[225].
Morphologically, normal renal cells displayed a homogeneous population
of cells with cobblestone appearance whilst cells of RCC showed flattened
polygonal morphology and many lipid vesicles in the cytoplasm. Figure
4.22. In addition to the distinguishable morphological features of primary
normal and tumour cells, final diagnoses of all RCC tissues were concluded
by a specialised pathologist after performing all required histopathological
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work (Appendix 1) on tissues taken from the same tumorous lesions used
for the primary cell cultures. The purpose behind these experiments was to
test the response of these primary normal and tumour cells to the infection
by ORCTL3-adenovirus. The cells were maintained in culture until the
required numbers of cells were obtained, typically after passage 4 to 7 which
could be reached in two to four weeks. The infectivity and the required
concentration of the virus was first tested by infecting normal and tumour
cells of patient #1 with two different MOIs (5000 and 10000). Examining
the expression of ORCTL3 in the infected cells by immunostaining revealed
that both cells were infectable to a very comparable level and that the
higher MOI did not significantly improve the infection efficiency. Figure
4.23A. Therefore, it was decided to quantify apoptosis that resulted from
infecting the cells with the lower MOI to maintain more specific conditions
in the cells. Figure 4.23B shows how ORCTL3 overexpression in primary
tumour cells remained a very specific apoptosis-inducing signal causing
around 30% cell death in tumour cells and exerting no toxicity in normal
cells. Figures 4.23C and E confirmed the previous finding and showed
the same outcome in tissue samples from two other patients. Figures
4.23D and F confirmed similar infection efficiencies in both normal and
tumour cells.
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Figure 4.22: Representative morphology of confluent monolayers
of primary normal and malignant renal cells. Left panel: primary
normal human proximal tubular epithelial cells. Right panel: primary
human renal cell carcinoma cells. Pictures were taken between day 2 and
7 after isolation.
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Figure 4.23: Adenovirus vector expressing ORCTL3 is inducing
apoptosis only in primary renal tumour cells and not in their
normal counterparts. (A) Normal and tumour kidney cells from patient
#1 were infected with MOIs of 5000 and 10000 of ORCTL3 expressing
virus. 48hrs after infection, the expression of ORCTL3 was measured by
immunostaining the cells with a labelled antibody against HA that was
analysed by flow cytometry. Bars represent the means of HA-positive cells
from one representative experiment where each sample was processed in
duplicate, (n=2).
144
Figure 4.23: contd. (B) and (C) Normal and tumour cells from patient#1
and 2, respectively, were infected with an MOI of 5000 of ORCTL3- and
luciferase- expressing adenovirus and apoptosis was quantified by double
staining with DiOC6/PI and flow cytometry analysis using channel FL1
and FL3. Data are the means of triplicates for patient#1 or duplicates
for patient#2 from one representative experiments, n=3 or 2, respectively.
The background level generated by luciferase infection was subtracted from
each reading. (D) Immunostaining to evaluate the expression levels of
ORCTL3 in the infected cells of patient#2. (E) Normal and tumour cells
of patient#3 were infected with ORCTL3 or luciferase adenoviruses using
Adbooster (Vector Biolabs) for the tumour cells (due to extremely low
infection efficiency). Apoptosis was quantified using DiOC6/PI staining.
Data are the means of duplicates from one representative experiment, n=2.
The background level generated by luciferase infection was subtracted from
each reading. (F) Infection efficiency of the viruses in cell from patient#3
using Adbooster was quantified by a GFP-expressing adenovirus in both
normal and tumour cells. GFP expression was quantified using FL1 channel
in flow cytometry. Bars represent the percentages of GFP positive cells
in infected normal and tumour cells from a duplicate of a representative
experiment. The figures above the bars are the mean intensities of the
measured GFP signals.
4.12 In vivo injection of ORCTL3-expressing virus to
induce apoptosis in Caki-2 xenografted mice mod-
els
Caki-2 cells were selected to conduct an in vivo experiment to demon-
strate the efficiency of the ORCTL3-expressing adenovirus vector to cause
shrinkage in the size of the formed tumour compared to tumours injected
with the luciferase expressing vector. The Caki-2 cell line is derived from
a human renal clear cell carcinoma. These cells were selected because of
reports that show the usage of them to generate xenograft tumours in nude
mouse[242]. Also, most other renal carcinoma cell lines showed downregu-
lation of coxsackievirus and adenovirus receptor (CAR). The level of CAR
expression in Caki-2 cells however, was not determined[242, 243]. To test
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the sensitivity of these cells to ORCTL3-expressing adenovirus vector, the
cells were infected with different concentrations of the virus and Figure
4.24 reveals that these cells can very efficiently undergo apoptosis after 48
hours of infection, indicating a fair expression of the CAR protein and the
suitability of these cells for subsequent in vivo experiments. Hence, 2X106
cells formed tumours after bilateral subcutaneous injections in twelve fe-
male Balb/c (nu/nu) mice. These tumours were injected with 5X109 of
ORCTL3-expressing adenoviruses on one side and the same number of a
negative control virus (luciferase-expressing adenovirus) on the other side.
The experiment is still on-going and results will be discussed upon the con-
clusion of the experiment.
Figure 4.24: The response of Caki-2 cells to ORCTL3 adenovirus. Caki-
2 cells were infected with different titers of adenoviruses expressing ei-
ther Luciferase or ORCTL3. 48 hours post-transfection, apoptosis was
assessed by DiOC6/PI staining and analysis by flow cytometry. Data are
the means of three independent experiments ± SD, n=3. Raw data were
normalised to transfection efficiency estimated by GFP. *p value<0.05 and
**p value<0.01.
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5 Discussion
5.1 Summary of the study
In this study I developed a novel model comprising normal and transformed
renal cells with an isogenic genetic background and with only one tumouri-
genic mutation each to test the synthetic lethal effect of ORCTL3 and
to help identify the pathway targeted by this protein. Normal CV1 cells
are not sensitive to apoptosis induced by ORCTL3. My results show that
transformation of these cells by the overexpression of H-Ras, Myc, mutant
p53, or E6 changes their status to apoptosis by ORCTL3 from resistant
to sensitive. Incomplete transformation introduced by E1A was not suffi-
cient to significantly activate the target/s of ORCTL3 upon its transfection
to a similar level. Figures 4.3 and 4.21. ORCTL3 is comparable and
sometimes more efficient than other longer known anticancer genes in this
cellular system. Figure 4.5. It was one of the main objectives of this
study to identify the target of ORCTL3 and its mode of action. My re-
sults indicate that ORCTL3 targets and most likely inhibits the enzymatic
activity of SCD-1. Figure 4.12. SCD-1 is upregulated in most cancer
cells and was also upregulated in the transformed CV1 cells generated in
this study. Its inhibition with a chemical compound had more pronounced
apoptosis effects on the transformed cells, which might explain the tumour-
specific effect of apoptosis induced by ORCTL3. Figure 4.11. Connecting
ORCTL3 and SCD-1 was inspired by the similar pattern of the ER stress
response triggered by the overexpression of ORCTL3[212] and the down-
regulation or the inhibition of SCD-1[222, 224]. However, the possibility of
the presence of other targets cannot be excluded.
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Apoptosis induction is an exclusive feature of the mouse and not the human
ORCTL3 gene. Figure 4.13. This could be either due to the low expres-
sion level of the human protein compared to the mouse or specific functional
sequences in the mouse protein that differ in the human homologue. The
mapping experiments that were performed in this study suggest that the
first four transmembrane domains of the mouse protein are sufficient to
induce apoptosis. Secondly, mouse TM domains 3 and 4 are necessary to
induce apoptosis by stabilising the protein and/or through the involvement
of a specific amino acid/s variance. Figures 4.14-18.
Finally, using an adenoviral vector as a carrier to transport the anticancer
gene ORCTL3 to the cells proved to be a very efficient approach. This
virus was used to infect normal and transformed CV1 cells (Figure 4.21),
normal and transformed primary kidney cells (Figure 4.23), and Caki-2
cells for xenografts in nude mice (Figure 4.24). In all cases, ORCTL3-
expressing adenovirus was “safe” on normal cells and an efficient apoptosis
inducer in transformed cells.
5.2 The continuous search for cancer therapeutic agents
“What do cancer cells have that normal cells don’t?. . . They have muta-
tions, and you can take advantage of those”
- Professor Paul Workman[244]
Cancer is a heterogeneous disease and this diversity is the reason why, de-
spite the tremendous amount of knowledge that has been gathered over the
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last few years about cancer genetics, metabolism, and pathogenesis, there is
no cure for cancer. The main challenge that any potential anticancer agent
faces is not its ability to kill cancer cells. Rather, the bottleneck lies in the
inability of many identified anticancer compounds to specifically kill cancer
cells at concentrations that cause no harm to normal cells. In other words,
developing anticancer agents that have high therapeutic indices and wide
therapeutic windows[245]. The reason for this lack of specificity is that
the majority of anticancer drugs target rapidly growing cells[246]. With-
out any further ability to selectively target only cancer cells, these drugs
can also affect normal dividing cells such as bone marrow haematopoietic
precursors, stomach, intestine and hair follicle cells[245]. Thus, developing
a drug that efficiently kills only cancer cells whilst sparing normal cells has
become the ultimate aim of any scientist who is investigating cancer. This
was how and why the concept of synthetic lethality was, and still is, utilised
for the search for specific anticancer agents. Synthetic lethality is a genetic
phenomenon that refers to cases in which the combination of two non-lethal
mutations yields lethality[245, 246]. One of these mutations can either be
loss-of-function in tumour suppressor genes or gain-of-function mutations
leading to oncogene activation. The principle of taking advantage of the
acquired mutations in cancer cells that expose new genetic vulnerabilities
in these cells and distinguish them from their wild-type counterparts was
the basis behind many systematic screens that were carried out to identify
potential pharmacological targets, for example by using siRNA or shRNA
libraries, and/or potential chemical products that can be used to target
cancer cells such as screening pharmacological compounds(drug-gene inter-
action screens). The best example for the effectiveness of synthetic lethality
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in cancer therapy is the BRCA/PARP model. Breast and ovarian cancers
with mutations in the tumour suppressor genes BRCA1 and BRCA2 can
be successfully treated with a chemical inhibitor of another DNA repair
enzyme PARP with remarkable mild side effects[247, 248].
The genome-wide screening carried out by Irshad et al. which led to the
isolation of ORCTL3 is unique. It was performed to identify synthetic
lethal genes with oncogenic E1A/E1B and Ras, which is frequently mu-
tated in many cancers but difficult to target directly using small molecule
inhibitors[249, 246]. High-throughput screening of cDNA, RNAi, and chem-
ical compounds has become a widely used experimental approach that al-
lows the interrogation of many potential biological modulators against a
chosen set of defined targets. Each type of screening has its advantages
and downsides. cDNA overexpression screen has a few advantages over
siRNA or compounds screens. For instance, the outcomes of cDNA screens
are usually genes and their encoded proteins. These genes can be devel-
oped more conveniently as future treatment agents and their mechanisms
of action and targets can be identified in the laboratory using conventional
molecular biology techniques. On the other hand, the outcomes of siRNA
screens are usually genetic targets. Developing agents that then specifically
target these genes might be a tedious endeavour. Moreover, RNAi screen
has two major potential problems. This approach is prone to high false
positive outcomes due to known off-target effects of si/shRNAs when they
recognize another unintended mRNA target and imped its translation. The
second problem arises when the exogenous si/sh/miRNA competes with the
endogenous sh/miRNAs for the available nuclear export complexes and pre-
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vents them from exerting their normal functions as a result of the oversat-
uration of the RNAi machinery. This problem can result in upregulation of
the genes normally regulated by endogenous miRNAs, causing toxic effects
and even lethality in mice[250]. Both problems can usually be solved by
using a second independent sh/siRNA. Moreover, thorough optimization of
RNAi screens to develop a robust transfection protocol in order to ensure
efficient knockdown is necessary. However, delivering si/shRNA in future
applications through a viral vector for example is more achievable due to
the short sequences of these constructs. The effect exerted by gene over-
expression is usually more specific than the effect of chemical compounds.
The overexpressed protein is usually localised to one or more organelle/s
and the downstream interactors can easily be identified, while chemical
drugs are usually not concentrated at one locale inside the cells and hence
are more likely to target various pathways. Although the idea of introduc-
ing an external gene into the cells might sound challenging, it all depends
on the vehicle that will be used to transport this gene into the cells, and
using the appropriate carrier can make the entire process completely safe
and efficient. Finally, a general limitation of many screens that use artifi-
cially created isogenic cell lines is that the genetic background and cellular
state do not strictly reflect “normal” cancer cells. Therefore, the genetic
interactions in these cells and in primary cancer cells that harbour the ge-
netic aberration are not necessarily the same. However, due to the huge
amount of information that can be obtained from a single screen project,
I believe that each screen performed, even if it utilises artificial cellular
systems, adds to the information of genetic aberrations in cancer and will
contribute to a better understanding for tackling the disease.
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In this study, the model of normal and transformed CV1 cells represents a
“mini-screen” using the synthetic lethality concept and was done the op-
posite way. In this model, instead of looking for unknown mutations that
might become lethal in combination with known mutations in cancer cells,
I asked the question: which known tumourigenic mutation makes ORCTL3
overexpression lethal to transformed cells? The intention behind this ex-
periment was to move one step closer towards identifying the pathway that
is targeted by ORCTL3. The answer I established for this question was
that ORCTL3 is more likely to target a pathway that is generally disturbed
in many transformed cells (in these settings) regardless of the causative mu-
tation.
H-Ras was used to transform these cells because mutations in the Ras fam-
ily onco-proteins are found in 20-30% of all human tumours making them
the most commonly mutated oncogenes in cancer cells[251]. Mutations
in the tumour suppressor gene p53 are found in over 50% of cancers and
are believed to be the most common alteration in cancer[252]. E6 on the
other hand, transforms cells by complexing p53 and targeting it for rapid
proteasome-mediated degradation, an abrogation of p53 functions that is
equivalent to the outcome of an inactivating mutation of p53[253]. c-Myc
was also introduced because it is found to be expressed at elevated level
in most tumours[254]. Of note, the increased population of cells that were
undergoing apoptosis in c-Myc transformed cells was not a surprise, as
this observation was reported in previous studies[96]. Each one of these
mutations was able to activate ORCTL3 in the transformed cells. Since
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none of these cells showed a higher proliferation index than the normal
cells (Figure 4.4), these results suggest that, unlike most established anti-
neoplastic agents that act against fast proliferating cells, ORCTL3 targets
other, more specific pathway/s in tumour cells. Interestingly, other anti-
cancer genes became also active when specific tumourigenic mutations are
introduced. The different efficiencies of the anticancer genes in different
transformed cells indicate possible distinct modes of action. It can also be
due to targeting a signal that is downstream of the introduced oncogene and
has not been “disrupted enough” for the anticancer gene to be activated.
To illustrate, these transformed cells are pools of transfected cells express-
ing varying levels of the oncogenes. If a certain anticancer gene needs a
certain level of the accumulation of protein x, downregulation of protein
y, or disruption of signal z, different effects of each gene are expected in
differently transformed cells. Cells transformed with E6 and p53 demon-
strate a good example. E6, as discussed above, is supposed to inactivate
p53, therefore a comparable effect of each anticancer gene is expected to
be evidenced in cells transformed with E6 and p53. However, this was not
always the case. In Figure 4.5.A, Mda-7/IL24 induced apoptosis in p53
but not in E6 transformed cells. Does Mda-7 need a certain level of p53
inactivation that was not achieved by E6 in these cells? Likewise, Apoptin
was active in E6 but not in p53 transformed cells. It is already known that
Apoptin functions independently of p53[149], but did E6 introduction into
these cells cause another aberration, in addition to p53 inhibition, that was
necessary for apoptosis induction by Apoptin, such as a post-translational
modification that translocates Apoptin to the nucleus where it exerts its
tumour-specific apoptosis effect[255, 143, 256]? These questions are often
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reminders of the necessity to understand the functions and identify the
targets of these anticancer genes in order to make the most of them ther-
apeutically, especially with the rapidly-growing popularity of personalised
medicine in cancer treatment. At least under the settings used in this study,
ORCTL3 proved to be more efficient than the other anticancer genes. The
relatively inefficient apoptosis induction observed in all transformed cells
can be due to the noticeably reduced transfection efficiencies in these cells
or due to the fact that a pool of transfected and selected cells were used
instead of selected single colonies. This approach was adopted to keep a
heterogeneous population of cells to recapitulate the wide heterogeneity
observed in the tumour tissues[235, 236]. Overexpressing E1A in CV1 cells
did not result in the same level of ORCTL3 activation as detected in other
transformed CV1 cells, and this was not surprising. Adenovirus E1A is not
sufficient to transform primary cells on its own[257]. Complete transforma-
tion of the cells requires the cooperation of both adenovirus proteins, E1A
and E1B[258]. The results of E1A transformed cells with the overexpres-
sion of ORCTL3 and the other anticancer genes suggest that their effects
are extremely specific and can only be seen in completely transformed cells.
On the other hand, they also raise a warning that these genes might not act
on early transformation events should they be used as treatment agents.
Once again, this is another example why identifying the mode of action of
these anticancer genes is a necessity, and this is what I tried to achieve for
ORCTL3 in this research.
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5.3 ORCTL3 targets SCD-1 and activates an ER UPR
The advantage of working with anticancer genes is the possibility of iden-
tifying their mechanism of action and revealing new targets for cancer
treatment. TRAIL, Apoptin and Par-4 are good examples. However, al-
though some of Apoptin’s and Par-4’s downstream signalling have been
described, it is still unknown how these revelations can be applied in the
clinic[176, 145]. Recombinant human TRAIL and its agonists, on the other
hand, have made it to phase I and II clinical trials. Nevertheless, even
though its mechanism of action is well understood, its specificity against
tumour cells could not be explained thus far[259]. In this study, identifying
the target/s of ORCTL3 was one of the main objectives, not only to explain
the tumour-specific effect of ORCTL3 and to understand the mechanism of
action of its newly discovered non-physiological function, but more impor-
tantly to pave the way for this gene to make it to the clinic as an anticancer
agent. According to the results obtained from this study, one main target
of ORCTL3 in transformed cells was found to be the enzymatic activity of
stearoyl-CoA desaturase1 (SCD-1). The connection between the two was
first suspected when Minville-Walz et al. and Masuda et al. showed par-
tially induced UPR markers (ATF4 but no BiP activation) when downreg-
ulating or inhibiting SCD-1[222, 224]. This partial UPR was also detected
when ORCTL3 was overexpressed in the cells[212]. Looking at more UPR
markers, I showed induced splicing of XBP-1 upon ORCTL3 overexpres-
sion, a signal that was also detected upon SCD-1 downregulation[222].
The same study by Miniville-Walz et al. discussed an upregulation of
CHOP as a result of SCD-1 downregulation. However, in my experiments
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ORCTL3 expression did not increase CHOP levels in HeLa cells. Upon
closer inspection the western blot results presented by Miniville-Walz et
al., are in fact arguable and the reported increase in CHOP is not conclu-
sive. Another explanation could be that SCD-1 downregulation triggers an
additional signal that is not produced upon its inhibition by ORCTL3.
The unique and partial ER-UPR induced by SCD-1 downregulation and
ORCTL3 overexpression was not the only reason why this study suggests a
connection between the two proteins. My results demonstrate how the sup-
plementation of oleic acid, a product of the SCD-1 enzyme, could partially
rescue the transformed cells from apoptosis induced by ORCTL3. Indicat-
ing cytotoxicity that results from the depletion of the MUFAs produced
by SCD-1 rather than the build-up of the toxic pathway intermediates or
SCD-1 substrates[260]. The incomplete inhibition of ORCTL3’s toxicity
by oleic acid supplementation can be explained by its inefficient uptake by
the cells and/or some toxicity produced by the build-up of SCD-1’s sub-
strate. A complete rescue of the cells with impaired SCD-1 by exogenous
oleic acid supplementation was not always reported. In fact, Miniville-Walz
et al. failed to show any rescue of cells with downregulated SCD-1[222].
Moreover, supplementation of oleic acid was not always sufficient to rescue
HeLa cells from apoptosis induction by ORCTL3. (Data not shown). This
could be due to variations in the tolerance levels of accumulation of the
SCD-1’s substrates in different cells.
It seems from these results that ORCTL3 inhibits the enzymatic activ-
ity of SCD-1. The importance of which will be discussed below, but this
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suggestion is also supported by the specific and efficient reduction of apop-
tosis induced by ORCTL3 when SCD-1 was co-transfected. Moreover, the
immunoprecipitation results suggest that there is a physical interaction be-
tween the two proteins. Figure 4.12.
The fact that SCD-1 is commonly overexpressed in cancer cells, which was
also seen in the transformed cells generated in this study (shown in Figure
4.11A), might explain the tumour-specificity of ORCTL3. The upregula-
tion of SCD-1 in cancer cells can be one of the many changes in metabolism
that cancer cells adopt during the transformation process. Alterations in
metabolism in cancer cells was first reported 70 years ago when Otto War-
burg observed an elevated uptake of glucose and an increased glycolytic
rate in cancer cells, which results in aerobic glycolysis and an increase in
the production of lactate, a phenomenon known as the Warburg effect[261].
Nowadays, aberrations in metabolism in cancer gained more appreciation
simply on the basis that the increase in proliferation makes it necessary for
the cells to increase their ATP production, macromolecule synthesis, and
redox status[262]. One of these metabolic changes is the increased synthesis
of mono-unsaturated fatty acids (MUFA) that are required for the increased
biosynthesis of the membrane’s phospholipids due to the high proliferation
rate. This alteration requires a continuous upshift in the activity of SCD-1
in these cells because of their dependency on (or addiction to) its products,
MUFAs. Inhibiting this enzyme, even though it is expressed to a higher
level in cancer cells than in normal cells, results in a shortage in MUFAs
supply that cannot be tolerated by the dependent cancer cells, and hence,
cell death. Whilst normal cells are usually more adaptive to this subtle
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change in metabolism since the existence of high amount of MUFAs is not
a necessity for survival.
The transformed CV1 cells generated in this study did not show higher
proliferation rates than their WT counterparts, yet they still showed an
increased SCD-1 expression level (H-Ras and p53 transformed cells) and
they still responded to ORCTL3 apoptosis induction. This can be ex-
plained by two different hypotheses. The first explanation might be that
the increase in SCD-1 level in transformed cells is triggered by a signal
other than increased proliferation, for example to overcome what is known
as oncogene-induced apoptosis or senescence[263, 264]. These two signals
are considered as tumour suppression mechanisms that are usually initi-
ated by tumourigenic mutations in oncogenes, such as Ras and Myc, or
tumour suppressor genes, such as p53, as a natural cellular response to
stress stimuli to maintain cellular homeostasis. These protective signals
are usually initiated during the transformation process and the outcome
is either cell death or senescence, - or transformation when the former
events fail to take place. If one assumes that SCD-1 has an inhibitory ef-
fect against oncogene-induced apoptosis or senescence, which may lead to
a selection of those cells that are transformed and have upregulated SCD-
1, that might explain the increased SCD-1 levels in transformed cells that
do not proliferate faster, such as transformed CV1 cells. However, this
hypothesis needs more work to be proven, especially when one asks how
can cells tolerate the increased amount of MUFAs if they were not used up
for membrane synthesis? They could be stored as vacuoles that are often
seen in transformed cells in culture. The other explanation could be that,
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although there were no apparent differences in proliferation rates between
transformed and WT CV1 in these experimental settings, differences might
have been masked by the simultaneous increased rate of apoptosis induced
by the very same oncogenes that were introduced to transform the cells.
The later explanation cannot rule out that ORCTL3 might be targeting
cells with higher proliferation rate that are MUFA-dependent but more
work is needed to confirm this.
SCD-1 catalyzes the introduction of a double bond between carbons 9 and
10 of several saturated fatty acids such as palmitic acid (C16:0) and stearic
acid (C18:0) to produce the monounsaturated fatty acids palmitoleic acid
(C16:1) and oleic acid (C18:1)[265]. Different studies revealed an important
role of SCD-1 in different cellular processes[265]. SCD-1 is a known key
role player in membrane synthesis and fluidity. Interestingly, involvement
of this enzyme’s function was evidenced in cancer development[200, 210],
neural regeneration[266] and brain development[181], and obesity. SCD-
1’s role in obesity has been the focus of hundreds of studies that looked at
the enzymatic activity of SCD-1 as a therapeutic target[267]. Most of these
studies concluded that targeted inhibition of SCD-1 is extremely effective in
preventing diet-induced obesity[267]. This finding suggests an interesting
connection between obesity and cancer through SCD-1. The connection
between obesity and cancer has been established through different stud-
ies that concluded that obesity was associated with an increased risk of
developing cancer[268, 269], and increased risk of death due to prostate
cancer metastases[270]. Due to the abnormally elevated levels of SCD-1
significantly linked to the metabolic alterations found in obesity, as well
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as diabetes, and the upregulated levels of SCD-1 evidenced in cancer cells,
SCD-1 is suggested to be the mutual molecular link between cancer and
obesity[193]. Its inhibition is positively correlated to preventing obesity
and in this study I propose that its inhibition by ORCTL3 overexpression
also results in toxicity to cancer cells.
Although the interaction between ORCTL3 and SCD-1 was clearly estab-
lished in this study and might explain the specificity of ORCTL3’s induced
toxicity, the existence of other additional targets of ORCTL3 cannot be
ruled out. The involvement of the ARCosome in the signal induced by
ORCTL3 suggests an activation of a complex downstream in the signal-
ing cascade, and the localization of SCD-1 in the ER membrane can also
mean that an indirect interaction between ORCTL3 and the ARCosome is
responsible for the effect.
While highly specific compounds against SCD-1 have already been devel-
oped, ORCTL3 caused higher apoptosis in transformed CV1 and a lower
background in normal CV1 cells compared to the SCD-1 inhibitor used in
this study, indicating a more precise targeting by ORCTL3 and/or less ac-
cumulation of SCD-1 substrates that might be poorly tolerated by normal
as well as transformed cells[267]. In fact, SCD-1 inhibitors have been re-
searched for a long time in connection with obesity and diabetes. Results
show protective effects of SCD-1 inhibition on obesity, hepatic steatosis,
and insulin resistance. However, SCD-1 inhibition in recent studies has
uncovered some side effects due to the accumulation of SCD-1 substrates
(SFAs) which are largely evidenced to be potent proinflammatory molecules
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linked to a number of inflammatory diseases such as atherosclerosis[271], β
cell dysfunction[272, 273, 274, 275, 276, 277, 278], steatohepatitis[279, 280]
and colitis[281]. These side effects should be looked into when considering
ORCTL3 for any in vivo study. The lower backgrounds observed in normal
cells upon ORCTL3 expression compared to the treatment with the SCD-1
inhibitor (CAY10566), and the high concentration of CAY10566 that was
needed to achieve a similar level of apoptosis induced by ORCTL3 make
it sensible to anticipate that ORCTL3 might not cause the same level of
adverse effects experienced when using chemical inhibitors of SCD-1. Does
ORCTL3 trigger another tumour-specific signal? Is it tumour specific be-
cause it does not cause an accumulation of SFAs that are generally toxic
to all cells? The latter question can be addressed by comparing the SCD-
1’s substrate:product ratios upon ORCTL3 expression and SCD-1 chemical
inhibition. Finally, to further improve the specificity and efficiency of OR-
CTL3, it was essential to identify the minimal functional domain of the
protein.
5.4 The identification of the minimal functional do-
main of ORCTL3
An interesting connection between the physiological function of ORCTL3
and the enzymatic activity of many enzymes could be proposed. In the
study by A. Bahn et al.[217], ORCTL3 was shown to be a Nicotinate trans-
porter. Looking at the nicotinate function in the cell, it is a precursor, along
with nicotinamide, of the coenzymes nicotinamide-adenine dinucleotide
(NAD+) and nicotinamide-adenine dinucleotide phosphate (NADP+). The
reduced forms of NAD+ and NADP+, NADH and NADPH, respectively,
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are important cofactors in several hundreds of redox reactions. Given its
transport function, the overexpression of ORCTL3 can, theoretically, dis-
turb many cellular pathways and functions. This was the background for
my mapping experiments. The results shown in this study suggest that
ORCTL3 overexpression induces apoptosis via a signal that is independent
from its transport activity. The first indication for this proposition is the
finding that a construct of only the first four TM domains of the mouse
ORCTL3 was sufficient to induce very efficient apoptosis in the cells when
overexpressed. If the apoptosis induced by this construct was normalised to
its expression level, its effect looked comparable to the WT mouse protein,
even though its transport activity is very likely to be significantly reduced
or impaired due to the deletion of 8 transport channels of the protein.
Figure 4.15. The second indication that apoptosis induction takes place
independently of the protein’s physiological function is the finding that hu-
man ORCTL3, although is should have the same physiological function as
mouse ORCTL3, does not induce apoptosis when overexpressed in the cells.
Figure 4.13. Whether this lack of activity was due to reduced expression
and stability of the protein or due to amino acid variations between the
two proteins was the focus of the domain swapping experiments that fol-
lowed. Transferring TM domains 3 and 4 from human to mouse did not
alter its stability but did not lead to apoptosis. Figure 4.18. This find-
ing, although surprising as interactions with other proteins should be more
conserved in the same species, indicates that the two mouse TM domains
are involved in apoptosis induction via an additional specific function other
than just providing enough stability to the protein.
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The results also indicate that at least two mouse TM domains, either 1 and
2 or 3 and 4 are required for an increased stability of the protein. How-
ever, accumulation of the protein in the cells on its own is not sufficient for
apoptosis induction as the construct with the human TM domains 3 and 4
shows. Therefore, mouse TM domains 3 and 4 are necessary for apoptosis
induction.
Having another look at the deletion constructs produced in this study,
a unique expression pattern can be observed. The only constructs that
showed good expression levels were the ones with the first two or four
transmembrane domains. This pattern can be explained by the membrane
protein synthesis mechanism:
When a membrane protein is synthesised and inserted in the rough ER
membrane before folding, it is inserted in a certain orientation that is re-
tained throughout the transportation process of the protein via transport
vesicles to its final destination such as the plasma membrane or Golgi vesi-
cles membrane. Each membrane-spanning α-helix in these proteins acts
as a topogenic sequence. Topogenic sequences are specific hydrophobic
sequences of amino acids in membrane proteins that function in differ-
ent ways to determine the orientation of the protein in the membrane.
The first α-helical segment in a multiple membrane-spanning protein is an
internal uncleaved signal-anchor sequence, which directs the ribosome to
the ER membrane and initiates the transport of the growing polypeptide
across the ER membrane, the second hydrophobic α-helix is a stop-transfer
membrane-anchor sequence, which stops the transfer of the protein through
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the membrane whilst this same sequence remains anchored in the mem-
brane. As a result of this structure, the first two transmembrane α-helixes
are expected to insert into the membrane as a hairpin and the protein
chain will continue to grow into the cytosol. According to this model, the
third α-helix would be another internal uncleaved signal-anchor sequence
and the fourth another stop-transfer membrane-anchor sequence. Thus,
helixes 3 and 4 would insert into the membrane as hairpin, just like helixes
1 and 2. All transmembrane domains could insert into the membrane this
way[282, 283]. Figure 5.1. Deletions that disturb this signal sequence
order might affect the proper insertion of the protein into the ER mem-
brane and therefore proper folding and/or transportation. In this study
this effect is believed to be more pronounced in the smaller proteins and
to a lesser extent in the bigger ones when the protein has more than four
transmembrane domains. Only transmembrane proteins that are correctly
inserted in the ER membrane are then folded properly and, if necessary,
allowed to be transported to their different cellular locations to function.
Any mutation that prevents the protein from the correct insertion in the
ER membrane and, hence, proper folding produces unfolded, misfolded, or
incompletely folded protein, which frequently results in proteins that are
degraded in the ER by the ER proteolytic machinery as a quality control
measure[282].
The reason behind designing three different constructs of TM domains 3
and 4 (illustrated in Figure 4.16) was the recognition that biosynthesis
of transmembrane proteins is not a straight forward mechanism. There-
fore, in addition to the construct that harbours the two TM domains only,
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Figure 5.1: A cartoon showing the mechanism of transmembrane
protein synthesis and insertion into the ER membrane.The N-
terminal α helix functions as an internal, uncleaved signal-anchor sequence
(red), directing binding of the polypeptide chain to the rough ER mem-
brane and initiating cotranslational insertion. Following synthesis of helix
2, which functions as a stop-transfer membrane-anchor sequence, the first
two α- helices move out of the cytosol into the ER bilayer, anchoring the
nascent chain as an α-helical hairpin. The C-terminus of the nascent chain
continues to grow in the cytosol. Subsequent α-helical hairpins could insert
similarly. The signal recognition particle is important for the initiation of
synthesis and the insertion of the first two α- helices. Note the different
charges of amino acids flanking the transmembrane domains.
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two additional constructs were engineered. One that also includes the N-
terminus cytosolic part of the protein (NTM34), because it was thought to
be important for signal recognition particles to initiate protein synthesis,
and a third construct that also includes, in addition to the TM domains
and the N-terminus, two additional positively charged amino acids (Argi-
nine) at the N-terminal side of the protein (NPosTM34). These were added
because it is known that hydrophilic, charged amino acids residues flank-
ing the α-helical transmembrane domains determine the orientation of the
amino acid sequence in the membrane. This setting follows the “positive
inside rule”, which means the flanking segment with the most positively
charged and the fewest negatively charged side chains remains on the cy-
tosolic face of the membrane[282].
Finally, identifying the minimal functional domain of ORCTL3 might be
necessary when ORCTL3 is used in any future application to minimize pos-
sible cross-interactions and increase specificity. To make use of the mapping
experiments above, it is necessary to identify a method by which mouse
TM domains 3 and 4 can be stabilised and correctly retain their secondary
structure they normally form when expressed within the full length protein
backbone. The correct, biologically relevant helical conformation is crucial
for peptides to bind their intended targets. Chemical modifications of the
peptides such as the use of hydrocarbon bridges to either crosslink side
chains of specific residues or mimic intramolecular hydrogen bonds with
carbon-carbon bonds is one way of stabilising short peptides in cells[284].
This modification can be further explored to stabilise TM domains 3 and 4
and test their apoptosis effect. However, the major question remains: how
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can ORCTL3 protein or even the small peptide (TM34) be delivered to the
cells?
5.5 Proof of concept: first in vitro applications of OR-
CTL3
Treating the cells with ORCTL3 involves the expression of an exogenous
gene in the target cells. Delivering DNA that carries the therapeutic genetic
sequence into the cells in an in vivo system is a challenging undertaking.
The DNA has to overcome uptake by non-targeted cells, cross the mem-
brane barrier, overcome degradation by nucleases, and finally reach the
nucleus to be expressed in the target cell[285]. Three available vehicles
are currently available to deliver genes into cells. The first gene deliv-
ery method used in clinical trial was the viral vector in 1990[286]. Viral
vectors are genetically modified viruses with abolished replication ability.
They are known for their high delivery efficiency to many cells and are usu-
ally the preferred approach for gene delivery. This is evidenced by the fact
that 67% of clinical trials conducted so far employed viral vectors[285].The
other two methods are the non-viral vectors such as synthetic and natural
compounds which are less toxic than the viral vectors and more flexible for
the size of gene they can carry. These include bacteriophages-, liposome-
and polymer- based non-viral vectors and were employed in around 24% of
clinical trials. The last approach is the physical methods where physical
force is used to transfer the gene into the cells[285], for example, by electro-
poration or sonoporation[285]. Thus far, there is no perfect gene delivery
method for all applications; instead, for each specific application a unique
delivery carrier has to be developed to target the desired cells with high
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delivery efficiency and appropriate amount of gene product for a required
period of time[285]. For this study, an adenoviral vector seemed to be the
optimal delivery carrier for ORCTL3, due to its known high delivery effi-
ciency, given that ORCTL3 needs to be expressed to a high level for its
apoptosis effect.
Renal cancer is the sixth leading cause of cancer-related death in the
USA. With over 30,000 new cases diagnosed every year, it is responsi-
ble for around 12,000 deaths annually[287, 288]. Renal cell carcinoma
comprises 85% of renal cancers in adults and more than 3% of all adult
malignancies[225]. Clear renal cell carcinoma is the most common form of
renal cancer accounting for 80-85% of renal cell tumour[287, 289]. So far,
there is barely any systematic treatment for dispersed renal tumours and
the therapy of renal tumours relies primarily on surgery. Although pre-
vious data showed that ORCTL3 is active against a wide range of cancer
cells[212], in this project the main focus was on renal cancer. The increased
apoptosis exerted by the adenovirus expressing ORCTL3 and the apoptosis
effect that is seen by the mouse and not the human ORCTL3, seemingly
caused by the increased stability of the mouse protein in the cells, strongly
indicate that it is essential to efficiently introduce ORCTL3 gene into the
target cells, should it be used for therapeutic purposes. Primary human
cells cultures might be the closest in vitro model to what exactly happens
in these tumours in vivo, especially if cells were minimally passaged. The
results obtained in this study promise a very specific effect to tumour cells.
However, the efficiency of the effect so far might not be ideal and this could
be due to low infection efficiency with the virus rather than the effective-
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ness of the ORCTL3 apoptosis-inducing signal per se in these cells. The
low infection efficiency of the adenoviruses in these cells can be explained
by the well-known loss of or decreased expression level of coxsackie and
adenovirus receptor (CAR) in renal tumour cells. CAR is a high affinity
receptor for adenovirus type 5 (the same type used in this study)[243]. It
is suggested that the loss or decreased expression of CAR may be an early
event in renal cancer progression[243]. In this study, it is speculated, from
the infection efficiency of the three different sets of the patients’ samples,
that patient1 and 2 might express CAR at a decreased level and that might
be the reason why infection efficiency was not very high in both sets and
the effect of ORCTL3 could only be seen after 48 hours whereas in most
of the other experiments the effect of ORCTL3 could usually be detected
24 hours after transfection/infection. Results for Patient 3 suggest that
these cells completely lack the expression of CAR and hence could not
be infected without a booster kit that is probably targeting the virus to
a different receptor (no specific information was available on the booster
reagent from the manufacturing company). Therefore, the use of a WT
adenoviral vector as a carrier of ORCTL3 in renal tumour might not be
the ideal way to effectively transport the gene into the cells and other car-
riers such as lentivirual vectors might be better alternatives in this case.
However, a lentiviral vector was tested to deliver ORCTL3 into HeLa cells
earlier during the time course of this project, and even though all cells
scored positive for ORCTL3 expression, apoptosis was hardly detectable
due to a very low but universal expression of ORCTL3 in all cells. (data
not shown). These results made us believe that in order for ORCTL3 to
elicit its apoptosis effect, it has to exceed a certain level of expression in
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the cells. Nonetheless, lentiviral vector efficiency might be cell-specific. It
can still be tried in renal cells and might deliver better outcomes than in
other cells. Once again, and just like people driving different brands of
cars, each gene needs a different vehicle to be transferred to different cells.
Primary cell culture is a very valuable tool to start any in vivo investiga-
tion especially to test the safety or the efficacy of a certain drug or agent.
However, there are a number of limitations. Unless one starts with a big
enough size of tumour or normal tissue in the isolation process, which
might not be feasible in all cases, these cells are very slow to prolifer-
ate in general and that is also very dependent on how confluent they are.
This might make it necessary to keep the cells in culture for longer time
than desired and that might result in cells acquiring mutations/epigenetic
changes whilst they are in culture. This will result in misleading outcomes
of the downstream experiments. The cells’ slow proliferation rate might
also mean some restrictions with how many experiments one can perform
before the cells cease proliferation completely as they are not immortal and
hence cannot be kept in culture for longer than passage 10 in the best cases.
Caki-2 cells were chosen for the on-going in vivo experiments because they
are human renal tumour cells that have shown positive results when infected
with ORCTL3. Assuming they express CAR sufficiently, they were chosen
despite the fact that they are known to grow slowly in vivo. The in vivo
trial is currently pending and results will be discussed upon the conclusion
of the experiment.
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6 Future Directions
In this study, I characterised the mechanism of action of ORCTL3 as a
tumour-specific apoptosis inducer gene by identifying its interaction with
the enzyme SCD-1. This interaction might stand as the basis of the tumour
specific effect of ORCTL3, especially after identifying the role and signif-
icance of SCD-1 in tumours and the differences of SCD-1 regulation and
function in tumour versus normal cells. The physical interaction shown in
an immuneprecipitation, the rescue of the ORCTL3-transfected cells with
oleic acid supplementation, and the SCD-1 overexpression in the trans-
formed cells are all very strong indicators that ORCTL3 and SCD-1 in-
teract to induce apoptosis and this effect is probably seen because of the
inhibition of the enzymatic function of SCD-1 by ORCTL3. However, more
functional studies might support this finding even better. For example,
comparing the ratios between the substrates of SCD-1 and its final prod-
ucts in cells with overexpressed ORCTL3 and negative control-expressing
cells might be very informative. The approach that can be used to address
this is any suitable lipid measurement technique, for example lipid mass
spectrometry especially with the use of radiolabelled substrates. Moreover,
although the differences in SCD-1 expression and function in normal and
transformed cells are addressed very thoroughly in many studies, it would
be interesting to study how these differences change the response of the cells
to ORCTL3. This can be achieved, for example, by examining whether
ORCTL3 and SCD-1 physically interact also in normal cells compared to
transformed cells. Also, whether overexpressing ORCTL3 in normal cells
would change the ratio between the substrates and the products of SCD-1
when the lipid measurement experiment takes place. These experiments
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will allow to identify the exact difference between normal and transformed
cells that activates ORCTL3 for apoptosis induction, because so far it is
not clear whether it is the dependence of only the transformed cells on
high SCD-1 activity that is inhibited by ORCTL3, whether it is an aberra-
tion or a mutation in, for example, SCD-1 in transformed cells that allows
ORCTL3 to bind to it and cause inhibition, or whether it is an indirect
interaction through another molecule that is specific to transformed cells.
All these questions can be raised at the end of this study especially because
the SCD-1 role in cancer development is not entirely clear. Even though
SCD-1 has been linked to increased neoplastic cell transformation and to a
protection process of the neoplastic cells against apoptosis[265, 195]. Hu-
man prostate carcinoma, for example, often showed strongly downregulated
or even diminished SCD-1 expression[290] and more recent data indicated
downregulation of SCD-1 in some tumour cell lines[210]. Moreover, the sur-
vival of human breast carcinoma cell line MDA-MB-468 was not affected
by SCD-1 knockdown[210]. It is still unclear whether SCD-1 plays a key
role in tumourigenesis and studies that look into this matter are necessary
because of the therapeutic potential this protein might possess. A very
simple experiment would be to test whether SCD-1 upregulation in the
cells functions to overcome apoptosis or senescence induced by oncogenic
transformation. For a start, this can probably be addressed by overexpress-
ing SCD-1 and a senescence-inducing gene or an oncogene that is known to
cause apoptosis and then looking for the reduction in apoptosis or senes-
cence compared to the control cells.
This study was mainly focused on the effect of ORCTL3 in renal cancer.
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It is known, however, that ORCTL3 acts on a wide range of tumours[212].
It would be interesting to expand the studies of ORCTL3 to other types
of tumours as well. For example, to study the variations in its efficiencies
on different tumours, to try more in vivo applications on other types of
tumours and also to study its mode of action in a range of cancer cells.
Examining ORCTL3’s effect on cancer cells with normal SCD-1 can be an
interesting starting point. If these cells still respond to ORCTL3 expression
and undergo apoptosis, this means that ORCTL3 might either trigger addi-
tional apoptosis signals to SCD-1 inhibition or that these cells, although do
not depend on high SCD-1 expression level, they are still highly dependent
on the presence of normal SCD-1 level for their survival or more sensitive to
the slight accumulation of its substrates, unlike normal cells which might
be more tolerant to these changes. If these cells do not respond to the
apoptosis signal induced by ORCTL3, however, it might strongly support
the finding of this study that increased SCD-1 level in transformed cells is
the main target of ORCTL3 but can also mean that ORCTL3 might not
be a universal therapeutic saviour of all cancers and will only target those
tumours with SCD-1 upregulation or dependency.
The results of ORCTL3 mapping experiments can be very valuable for any
future work. The smallest deletion construct (TM4) can always be opti-
mised for more efficient expression and apoptosis induction, by constructing
an adenovirus carrier for example which can be used instead of expressing
the WT gene. The mode of action of this construct can easily be examined
using the tools developed in this study. For instance, its interaction with
SCD-1 can simply be checked by a co-immunoprecipitation with SCD-1.
173
The use of a smaller construct, I believe, is more favourable especially for
any in vivo work and future clinical applications. TM domains 3 and 4 on
their own can always be tested and used once a technique is established to
stabilise and express them efficiently. Once the peptide can be stabilised,
by the chemical modifications discussed above for example, a potential ap-
proach can be the use of TAT-fusion protein to efficiently transduce the
cells with the peptide[256]. Furthermore, a recent effort could prove suit-
able for ORCTL3 in which an oncolytic adenoviral vector was developed
that is able to replicate in tumour cells which will amplify the initial viral
inoculum and destruct the infected tumour cell[285].
To conclude, this work described an effort to gain a deeper understanding
of the novel effect of the anticancer gene ORCTL3. The findings in this
study can be regarded not only as the first steps towards the prospect of
a therapeutic application of this unique gene but also as exciting scientific
insights, which might help us understand why tumour cells specifically
respond to ORCTL3 by committing suicide.
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Appendix 1
Histopathology reports for the renal tumour tissues obtained
from the tissue bank at Charing Cross Hospital
Patient #1
Histopathology
Histology of the right kidney confirms the presence of tumour. In better
differentiated areas this tumour is seen to exhibit a predominantly nested
and occasional tubulocystic architecture. It is richly vascular containing
a prominent supporting fibrovascular network. The constituent cells con-
tain clear and lightly granular eosinophilic cytoplasm with well defined cell
membranes. The described features are consistent with those of a clear
cell renal cell carcinoma. In these better differentiated areas the carcinoma
exhibits Fuhrman grade 2 and Fuhrman grade 3 nuclear features together
with focal grade 1 nuclear features. In areas the more differentiated carci-
noma merges with an element comprising a population of larger cells. In
this latter population, atypical hyperchromatic nuclear forms are identified
together with rhabdoid differentiation. However, these areas retain some
semblance of a nested architecture.
Summary Diagnosis
CLEAR CELL RENAL CELL CARCINOMA EXHIBITING SIGNIFI-
CANT RHABDOID AND FOCAL SARCOMATOID DIFFENTIATION
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Patient #2
Histopathology
The macroscopically noted tumour is a clear cell / conventional-type Renal
Cell Carcinoma with a nested/acinar/tubulo-cystic architecture composed
of small polygonal cells with mostly clear cytoplasm and well defined cyto-
plasmic borders. In areas, the cells have granular, eosinophilic cytoplasm.
The tumour cells have mostly central round vesicular nuclei with prominent
nucleoli seen with a X10 objective (Fuhrman Grade 3). Focally, adjacent
to an area of coagulative necrosis, there are aggregates of cells with bizarre,
large nuclei and prominent nucleoli. Some of these cells have multinucleate
nuclei. The features amount to focal Fuhrman Grade 4. There is a mild to
moderate patchy chronic inflammatory infiltrate within the tumour. There
is also haemorrhage and scattered pigment-laden macrophages. No sar-
comatoid or papillary areas are noted. The tumour appears confined to
the kidney with no evidence of invasion into perinephric or renal sinus fat.
No lymphovascular invasion is seen. Seven reactive hilar lymph nodes are
identified which show no evidence of carcinoma, (0/7). The ureter and
renal pelvis have normal urothelium present. The adrenal gland shows no
evidence of malignancy. The background kidney, away from the tumour, is
well preserved and essentially within normal limits.
Summary Diagnosis
CLEAR CELL/ CONVENTIONAL-TYPE RENAL CELL CARCINOMA
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Patient #3
Histopathology
Histology of this right partial nephrectomy confirms the presence of a tu-
mour. A significant proportion of the tumour is cystic. However, areas
exhibiting a nested and tubulo-cystic architecture also feature. The con-
stituent cells contain clear and lightly granular eosinophilic cytoplasm with
well defined cell membranes. They exhibit Fuhrman grade 2 and Fuhrman
grade 3 nuclear features. The lining epithelium of the cystic spaces is partly
attenuated and in areas fibrin lines the cystic spaces. However, where
lining epithelium remains, it exhibits a similar profile to that described
above. Overall, the described appearances are consistent with those of a
clear cell renal cell carcinoma. The carcinoma is richly vascular and con-
tains zones of haemorrhage and fibrin deposition together with aggregates
of haemosiderin laden macrophages. Blood and homogeneous eosinophilic
material also feature in the cystic spaces. Additional findings include areas
of oedema and focally a foreign body giant cell reaction to cholesterol clefts
is noted within the carcinoma.
Summary Diagnosis
CLEAR CELL RENAL CELL CARCINOMA
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